Dominican Scholar
Graduate Master's Theses, Capstones,
and Culminating Projects

Student Scholarship

5-2015

Modeling Uric Acid Kidney Stones Disease in D. melanogaster
using RNAi and Dietary Modulation
Hai T.H. Lu
Dominican University of California

https://doi.org/10.33015/dominican.edu/2015.bio.05

Survey: Let us know how this paper benefits you.
Recommended Citation
Lu, Hai T.H., "Modeling Uric Acid Kidney Stones Disease in D. melanogaster using RNAi and
Dietary Modulation" (2015). Graduate Master's Theses, Capstones, and Culminating Projects.
178.
https://doi.org/10.33015/dominican.edu/2015.bio.05

This Master's Thesis is brought to you for free and open access by the Student Scholarship at
Dominican Scholar. It has been accepted for inclusion in Graduate Master's Theses, Capstones, and
Culminating Projects by an authorized administrator of Dominican Scholar. For more information,
please contact michael.pujals@dominican.edu.

Modeling Uric Acid Kidney Stones Disease in D. melanogaster using RNAi and Dietary
Modulation

a thesis submitted to faculty of Dominican University of California
and the Buck Institute for Research on Aging
in partial fulfillment of the requirements
For the degree

Master of Science
in
Biology

By
Hai Lu
San Rafael, California
2014

Copyright by

Hai Lu

2014

Certification of Approval

I certify that I have read Modeling Uric Acid Kidney Stones Disease in D. melanogaster using
RNAi and Dietary Modulation
By Hai Lu,
and I approved this thesis to be submitted in partial fulfillment of the requirements for the
degree: Master of Sciences in Biology at Dominican University of California & the Buck
Institute for Research on Ageing.

___________________________________________
Dr. Pankaj Kapahi, PhD
Graduate Research Advisor
Professor at the Buck Institute for Research on Ageing

___________________________________________

Dr. Roland Cooper, PhD
Professor at Dominican University of California

___________________________________________
Dr. Maggie Louie, PhD
Dominican University of California Graduate Program Director

This page is left blank intentionally.

1

Abstract
In humans, the major predictor for gout and forming uric acid kidney stones is elevated
uric acid in the serum and urine respectively. It is known that uric acid is an end metabolite of
purine degradation in humans, but in other species from D. melanogaster to lower apes, uric acid
can be further metabolized by urate oxidase into readily excreted allantoin. We hypothesize that
if urate oxidase enzyme activity and dietary purine are both critical in uric acid kidney stone
formation, then urate oxidase knockdown in combination with dietary purine supplementation
will increase uric acid and induce uric acid kidney stone formation in D. melanogaster. Initially,
we confirmed urate oxidase knockdown and then elevation of uric acid as a consequence. We
then confirmed uric acid kidney stones formed as a consequence of urate oxidase knocked down
and a high purine diet. Next, we tested compounds used to treat gout or uric acid kidney stones in
humans using our model. We found that allopurinol and potassium citrate reduced uric acid
kidney stone formation in our model. We then tested whether compounds predicted to reduce
uric acid and uric acid kidney stones in humans, but not currently used as treatments, can reduce
uric acid kidney stone formation in our model. We found that methotrexate, hydrochlorothiazide,
and l-lysine were effective at reducing uric acid kidney stone formation. Lastly, we ran a
medium throughput screen of 117 natural compounds for inhibitors of uric acid kidney stone
formation using our model and found seven inhibitors.
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4

Introduction
No class of molecule consistently reappears in the large number of different biological

processes as purines, making them the most widely found alkaloid or nitrogen containing
heterocyclic compound in nature (Rosemeyer, 2004). Purines are components of molecules that
are essential to many cellular processes like DNA replication, transcription, translation, and
energy metabolism. Without purines, these essential processes could not occur and life could not
exist as we know it. Because purine structures are important to a large number of different
biological processes; purine de novo synthesis, salvage, degradation, and excretion is tightly
regulated across species ranging from humans to bacteria (Boss and Seegmiller, 1982; Gots et
al., 2009; Jurecka, 2009; Mandal et al., 2003; Mendz et al., 1997; Nudler and Mironov, 2004).
Disorders of purine degradation like gout and uric acid kidney stones have been well
documented in western literature since Greek times. In the Hippocratic Corpus written sometime
between 420-370 BC, the Greeks refer to gout by the word podagra, which literately means “the
un-walkable disease” (Singer and Underwood, 1962). The most common symptoms were painful
swelling and acute inflammation and arthritis of the first toe in the first metatarsophalangeal
joint, which can cause crippling loss of mobility, giving gout its Greek namesake. The
Hippocratic Oath indirectly mentions surgeons that specifically performed lithotomies, the
removal of stones from the body, a large number of which were uric acid kidney stones
(Edelstein, 1943). Patients with uric acid kidney stones or kidney stones in general experience
reoccurring episodes of extreme and severe pain that begins from the flanks or lower back of
their abdomen and progresses to the inner thigh or groin area that are called renal colic pain
(Preminger, 2007). Renal colic pain has been described as one of the strongest pain sensations
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known in the human experience and is accompanied by a host of acute symptoms like nausea and
vomiting to name only a few (Wolf, 2014). To understand gout and uric acid kidney stones,
diseases that have both been with humans since time in memorial, we need to examine how
purines are degraded and how they are eliminated.

4.1 Purine Structure
A purine is a conjugated heterocyclic organic compound containing a pyrimidine ring
fused with an imidazole ring. The pyrimidine is a six member coplanar ring containing two
nitrogen atoms (Fig. 1). The imidazole ring is also coplanar and consists of a five member ring
containing two nitrogen atoms (Fig. 1). Different types of purines like adenine and guanine bases
can be created by substituting different functional groups on the ring structure (Fig. 1).
Pyrimidines and purines are both nitrogenous bases that are structural components of nucleosides
and nucleotides. Nucleosides are pyrimidine or purine nitrogenous bases attached to a ribose
sugar at the 1’ carbon atom of the sugar molecule. Nucleotides are nucleoside structures with a
phosphate group attached to the 5’ carbon atom of the sugar.

4.2 Purines in cellular metabolism
Adenine has a primary amine group (-NH2) attached at carbon 6 of the purine ring while
guanine has oxygen double bonded at the same carbon and a primary amine group attached at
carbon 2 (Fig. 2). Purine (adenine and guanine) deoxyribonucleotides form hydrogen bonds
complementary to pyrimidine (thymine and cytosine) deoxyribonucleotides in a DNA double
helix. Information is stored in the sequence of purines and pyrimidine bases. With this genetic
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code, information contained in the DNA sequence can be replicated using one or both strands of
DNA. In the production of pre-mRNA, pyrimidine ribonucleotides are inserted complementary
to purine deoxyribonucleotides and vice versa. This pre-mRNA strand is processed and exons are
spliced together while the introns are excluded and degraded. The final mRNA sequence of
adenine, guanine, uracil, and cytosine ribonucleotides is produced. The mRNA sequence is used
as template for translation by the ribosome to synthesize the encoded polypeptide or protein.
Without adenine and guanine bases, replication, transcription, and translation all could not occur
as individual steps or together.

4.3 Purines in energy metabolism
Adenosine diphosphate (ADP) is also a component of various key molecules that are
involved in energy metabolism like adenine triphosphate (ATP), nicotinamide adenine
dinucleotide phosphate (NADPH), nicotinamide adenine dinucleotide (NAD), flavin adenine
dinucleotide (FAD), and Coenzyme A (CoA). For example, ATP is composed of a ribose sugar
with adenine attached to the 1’ carbon atom and three phosphate groups attached to the 5’ carbon
atom (Fig. 3). ATP serves as the main molecular battery that stores usable energy for the cell.
Chemical energy is stored between the bond of the β and γ-phosphate groups (anhydride bonds)
and this chemical energy is used during enzyme-catalyzed hydrolysis or phosphorylation to
power such processes as DNA and protein synthesis (Nelson and Cox, 2000). During the
elongation phase of DNA synthesis, DNA polymerase extends an existing DNA strand by adding
nucleotides complementary to a template strand and forming phosphodiester bonds between the
3’ hydroxyl group of the existing strand and 5’ phosphate group of the newly incorporated
nucleotide (Nelson and Cox, 2000). Elongation occurs uninterrupted to the leading strand of
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DNA, but the lagging strand must have their Okazaki fragments ligated together by DNA ligase,
which requires ATP (Nelson and Cox, 2000). Without ATP, DNA replication would be
incomplete. During translation, the production of aminoacyl-tRNA requires the initial reaction
between the α-carboxyl of an amino acid with the α-phosphate of an ATP molecule to form a 5’
amino-acyl adenylate (Nelson and Cox, 2000). Without ATP, aminoacyl-tRNAs would be
unavailable for protein synthesis. Energy contained in the structure of ATP is essential for both
DNA replication and protein synthesis to name only a few biological processes.
NADH is a triphosphate dinucleotide that is an extremely important cofactor involved in
many catabolic cellular processes. One nucleotide consists of a ribose sugar phosphorylated at
the 5’ carbon atom and adenine attached to the 1’ carbon atom. The second nucleotide consists of
another ribose sugar phosphorylated at the 5’ carbon atom and nicotinamide attached to the 1’
carbon atom. The two nucleotides are attached via a diphosphate bond between the 5’ carbons of
the two ribose sugars to form NADH (Fig. 4). In cellular metabolism, NAD+ accepts electrons
and NADH (the reduced form) donates electrons in redox reactions (Belenky et al., 2007). Redox
reactions in catabolic pathways like beta oxidation, citric acid cycle, and glycolysis reduce
NAD+ to NADH (Nelson and Cox, 2000). NADH can then act as a reducing agent and cofactor
in an anabolic process like gluconeogenesis (Sistare and Haynes, 1985). Without ATP or NADH,
energy metabolism would be severely compromised and essential cellular processes would cease.

4.4 Purine metabolism in humans and D. melanogaster
Purines are made available through either dietary intake (Bauer et al., 2006; Choi et al.,
2005), constructed de novo using intracellular components to form the purine ring, or recycled
via a salvage pathway (Kanehisa and Goto, 2000; Nelson and Cox, 2000). In both species, a
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dramatic change in the quantity of purines made available by one pathway can be compensated
for by modulating the other pathways accordingly. However, the elimination of purines has no
such natural compensatory mechanism for both species. The elimination of adenine and guanine
or its nucleotide derivatives converge downstream at xanthine (Kanehisa and Goto, 2000; Nelson
and Cox, 2000). There are no enzymatic catalyzed alternative routes for purine elimination that
bypasses xanthine for either species (Kanehisa and Goto, 2000; Nelson and Cox, 2000).

4.5 Purine degradation pathway to xanthine in humans and D. melanogaster
Xanthine consists of a purine ring with oxygen double bonded to a carbon at position 2
and 6 of the purine ring (Fig. 5). As shown in Fig. 6, xanthine can be created from the
degradation of adenine, guanine, or inosine nucleotides in humans and D. melanogaster (KG:
230)(Kanehisa and Goto, 2000). In both species, adenine monophosphate is first converted into
adenosine by 5’nucleotidase (KG:3.1.3.5)(Kanehisa and Goto, 2000). Adenosine is then
converted into inosine by adenosine deaminase and inosine is converted into hypoxanthine (the
oxidized form of xanthine) by nucleosidase (KG:3.5.4.4)(Kanehisa and Goto, 2000). Xanthine
oxidase (XO), a form of xanthine oxidoreductase, finally converts hypoxanthine into xanthine
(KG:1.17.3.2 & 1.17.1.4)(Kanehisa and Goto, 2000). To degrade guanine nucleotides, guanine
monophosphate

nucleotide

is

first

converted

into

guanosine

by

5’nucleotidase

(KG:3.1.3.5)(Kanehisa and Goto, 2000). Guanosine is then converted into guanine by
nucleosidase (KEGG: 2.4.2.1)(Kanehisa and Goto, 2000). Finally, guanine is converted into
xanthine by guanine deaminase (KG:3.5.4.3)(Kanehisa and Goto, 2000).
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4.6 Degradation of xanthine to uric acid and urate in humans and D. melanogaster
In both humans and D. melanogaster, xanthine is converted into uric acid (UA) by
xanthine oxidase (Fig. 6)(KG:1.17.3.2 1.17.1.4)(Kanehisa and Goto, 2000; Nelson and Cox,
2000). Xanthine can also be directly converted into urate (the ionic form of uric acid) by
xanthine dehydrogenase (XDH), another form of xanthine oxidoreductase (Eger et al., 2000;
Enroth et al., 2000). Uric acid consists of a purine ring with 3 oxygen atoms double bonded to
carbon atoms at position 2, 6, and 8 (Fig. 7). Uric acid is a diprotic acid with a pKa1 = 5.7 and
pKa2 = 10.3 with a solubility constant of 7 mg/dL at 25 °C (McCrudden, 2008). Uric acid can
reversibly form a singly charged urate anion ion (Fig. 7) that can conjugate with a base anion to
form a urate salt. At physiological pH, monosodium urate is the predominate salt and is nearly 50
times more abundant and more soluble than uric acid (Liebman et al., 2007). When pH
decreases, more insoluble uric acid forms rather than the more soluble urate salts. In summary,
every major step of purine degradation from the major nucleotide metabolites to uric acid and
urate is conserved when comparing humans and D. melanogaster.

4.7 Uric acid elimination in humans
Xanthine oxidoreductase is expressed in almost every type of human cell, tissue, and
organ from serum (blood) to lung, with the highest levels of expression occurring in the
cerebellum, skeletal muscle, liver, bone marrow, heart, and kidney (Sarnesto et al., 1996). Urate
can therefore be ubiquitously produced in humans from almost all cells, tissues and organs with
the largest amount being produced by the liver, muscles and intestine (Hediger et al., 2005).
Urate can also be produced by xanthine dehydrogenase in the serum. Once in the circulatory
system, urate is delivered to the glomerulus where it freely passes and enters the renal system.
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The nephritic filtrate that is produced then travels down the proximal convoluted tubule where
URAT1 (SLC22A12), OAT1/OAT3 (SLC22A11), and OAT4/OAT10 (SLC22A13) transporter
proteins reabsorb roughly 90 percent of the urate back into the circulatory system (Enomoto et
al., 2002; Terkeltaub et al., 2006). The remaining urate that is not reabsorbed will eventually be
excreted in urine.
In many other species, from flies to lower apes, urate oxidase (UO) can metabolize uric
acid into allantoin (Nelson and Cox, 2000). Allantoin is a uric acid molecule with the bond
between carbon 4 and nitrogen 3 oxidized losing the typical purine ring structure (Fig. 8).
Allantoin is nearly an order of magnitude more soluble than urate with a solubility constant of 57
mg/dl at 25 °C (Yalkowsky and He, 2003). Humans lost the ability to convert uric acid into
allantoin at some point during the Miocene epoch between 8 to 20 million years ago due to
sequential mutations to the promoter and then to the coding region of urate oxidase (Oda et al.,
2002). Thus, the urate oxidase gene is a so-called pseudogene in humans that is not expressed
(Kratzer et al., 2014).

4.8 Gout and uric acid kidney stones in humans
Because of the low solubility of uric acid (7 mg/dL at 25 °C), uric acid can precipitate out
of body fluids like serum or urine to form mineralized concretions. This can initiate gout and uric
acid kidney stones respectively. Gout is an inflammatory disease characterized by elevated uric
acid levels in the blood (hyperuricemia) that leads to deposition of monosodium urate crystals
within joints and eventually acute arthritis in patients (Wortmann and Kelley, 2005). Patients
with hyperuricemia are statistically more likely to develop gout (Choi et al., 2005; McGill and
Dieppe, 1991). A urate serum level greater than 7.0 mg/dl for extended periods of time is the

15
primary risk factor for developing gout (Campion et al., 1987). Around 8.3 million or around 3%
of population in the United States will develop gout at some point in their life (Zhu et al., 2011).
To prevent gout, a large component of the treatment effort focuses on lowering uric acid and
urate levels in the serum. Non-drug treatments to lower serum urate include reducing sodium
intake, reducing intake of purine rich foods, staying hydrated, losing weight if overweight,
decreasing alcohol intake, and regular exercise (Choi et al., 2005; Frassetto and Kohlstadt, 2011).
Drug treatments include nonsteroidal anti-inflammatory drugs, colchicines, and steroids (Nelson
and Cox, 2000), as well as probenecid (Sriranganathan et al., 2014), allopurinol (Akkasilpa et al.,
2004; Sriranganathan et al., 2014), and febuxostat (Schlesinger, 2010).
People with serum urate levels greater than 7.0 mg/dl are also more likely to develop uric
acid kidney stones (Wortmann and Kelley, 2005). Uric acid kidney stones are crystalline
concretions that form in the kidney or urinary track from precipitation and aggregation of uric
acid or urate in urine. The uric acid kidney stones can obstruct the urinary tract which causes
excruciating renal colic pain to patients. Two major predictors of forming uric acid kidney stones
in humans are urine pH and uric acid concentration in serum and urine (Dardamanis, 2013). In
the United States, kidney stones occurs in 6-12% of the general population (Stamatelou et al.,
2003). Of this 6-12% of people who experience kidney stones, 5-10% of them experience uric
acid kidney stones (Bushinsky, 2001), but rates of uric acid kidney stones can reach as high as
37.7% in the general population in other parts of the world like Iran (Halabe and Sperling, 1994).
The probability of forming uric acid kidney stones after the first episode increases by 23% and
each subsequent episode further increases the likelihood of uric acid kidney stone formation
(Trinchieri et al., 1999b). To prevent uric acid kidney stones, major effort is made to lower uric
acid and urate concentrations in the serum and urine of patients using pH alkalizing compounds
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such as potassium citrate (Maalouf, 2014; Sorkhi et al., 2011). Non drug treatments to reduce
serum uric acid and urate levels include reducing the intake of sodium, reducing the intake of
purine rich foods, staying hydrated, losing weight if overweight, decreasing alcohol intake, and
regular exercise (Choi et al., 2005), which are some of the same treatments recommended to gout
patients. Drug treatments available for uric acid kidney stones are benzbromarone (Akkasilpa et
al., 2004), and allopurinol (Halabe and Sperling, 1994).

4.9 D. melanogaster is a robust model organism for developing a model of uric acid
kidney stone disease
Is D. melanogaster well suited for our endeavor? The genome of D. melanogaster is
relatively small at 180 Mpb (vs. humans ~ 3,000 Mbp), composed of one pair of sex
chromosome (the first chromosome pair) and three pairs of autosomes (the second, third, and
fourth chromosome pair respectively) for a total of four chromosome pairs (Henderson, 2004).
Additionally, Drosophila genetics follow traditional Mendelian patterns of inheritance and can
easily be bred to produce flies of a desired genotype and phenotype (Henderson, 2004). Thus,
flies offer a great system in which genetic manipulation can be performed to induce uric acid
kidney stone formation.
Insects like D. melanogaster do not possess a vascular blood system, but instead have an
open circulatory system with a hemocoel that creates a blood-filled body cavity (Dow and
Romero, 2010b). Additionally, the renal systems of insects are also aglomerular and the
production of urine occurs through the malpighian tubules (the structural homolog of human
kidneys) as opposed to kidney as seen in humans (Beyenbach and Liu, 1996).
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Despite these gross anatomical differences, global transcriptome analysis between
humans and D. melanogaster shows conserved homology (Chien et al., 2002). When mRNA
analysis of important human and D. melanogaster transport proteins of the human renal system
and D. melanogaster malpighian tubules were performed, close conservation was observed
(Wang et al., 2004). Urate oxidase has been shown to be exclusively expressed in the malpighian
tubules during the larval and adult stage where it produces uric acid for excretion (Wallrath et al.,
1990). There have also been past studies that have proposed using or have used D. melanogaster
malpighian tubules to model the human kidney and renal system (Beyenbach et al., 2010; Dow
and Romero, 2010a). Previously, it had been shown that calcium oxalate kidney stones could be
induced by ethylene glycol and the stones were large enough to be measured and quantified
(Chen et al., 2011). Thus, given our current understanding, a D. melanogaster model of uric acid
kidney stones formation induced by genetics and dietary purine manipulation represents a logical
and powerful translational tool for modeling human uric acid kidney stones.
RNA interference (RNAi) utilizes endogenous short duplexed RNAs, either small
interfering RNAs (siRNAs) or small hairpin RNAs (shRNAs), which are processed by an
evolutionarily conserved mechanism for translational regulation. This conserved mechanism
depends on enzymatic cleavage of siRNA or shRNA by the protein DICER (Ketting et al., 2001).
The short processed RNA fragment is then incorporated into the RNA induced silencing
complex (RISC) (Parrish et al., 2000). RISC, guided by the loaded short RNA fragment, then
mediates the sequence specific silencing of target mRNAs through enzymatic cleavage
(Bernstein et al., 2001; Fire et al., 1998; Hammond et al., 2000; Zamore et al., 2000).
A knockdown model in Drosophila can be created by breeding for flies possessing the
desired transcription factor for an enhancer region upstream of a desired RNAi sequence. One
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commonly used system based on this principle is the Gal4/UAS system initial found in
Saccharomyces cerevisiae (Laughon et al., 1984) and subsequently adapted to D. melanogaster
(Fischer et al., 1988). In the D. melanogaster Gal4/UAS system, gene expression is regulated by
the binding of Gal4 transcription factors to UAS (Upstream Activation Sequence) enhancer
sequences that control expression of downstream genes (Brand and Perrimon, 1993). Different
patterns of Gal4 expressions are created by placing cell/tissue specific promoters upstream of the
Gal4 transcription factor and this construct is termed a driver (Duffy, 2002). There are many
drivers that have been developed to allow for reproducible spatiotemporal expression of genes
downstream of UAS sequences. Driver strains are commercially available as well as UAS
responder strain lines containing expressible RNAi sequences. A simple cross of a female fly
containing driver X and male fly of responder line Y RNAi allows for controlled spatiotemporal
expression of Y RNAi according to the promoter of X in the progeny. One variation of this
system is called GeneSwitch (GS) Gal4 system. In the GeneSwitch Gal4 system, Gal4
transcription factor activity is induced by progesterone or progesterone analog hormone binding
to Gal4 transcription factor (Ford et al., 2007; Han et al., 2000; Osterwalder et al., 2001; Roman
et al., 2001), which allows for stricter temporal and spatial control of gene expression based on
whether progesterone or a progesterone analog is administered as well as the rout of
administration.
Using RNAi in conjunction with food supplementation to induce kidney stones in D.
melanogaster has been accomplished in the past for calcium oxalate kidney stones (Hirata et al.,
2012). In the study, the authors knocked down dPrestin, an anion transporter, and found that
dPrestin influenced the excretion of calcium oxalate (Hirata et al., 2012). In another study,
mineralization of calcium oxalate stones were induced by ethylene glycol, hydroxyl-l-proline,
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and calcium oxalate (Chen et al., 2011). These mineralization of calcium oxalate stones were
reduced by dietary supplementation of potassium citrate (Chen et al., 2011). There have also
been numerous papers that have been written on the utility of the D. melanogaster for modeling
kidney disorders and uric kidney stones disease (Dow and Romero, 2010a; Knauf and Preisig,
2011; Miller et al., 2013). Can this be accomplished for uric acid kidney stones? Performing that
same procedure for uric acid kidney stones in D. melanogaster seems a logical step considering
the previous success of applying RNAi and food supplementation for modeling calcium oxalate
kidney stones and the success of modeling numerous other types of kidney disorders using the
fly model (Chen et al., 2011; Dow and Romero, 2010a; Hirata et al., 2012; Knauf and Preisig,
2011; Miller et al., 2013).
Food supplementation is an ideal method of administering compounds when performing a
screen for compounds to rescue a disease phenotype in D. melanogaster. Oral ingestion of food
containing supplemented compounds mimics oral ingestion by humans, which is the most
common method of consuming drugs. Oral ingestion of food supplemented with compounds also
has the advantage of easy administration. To introduce a compound, the food supplemented with
a compound can be easily exchanged in place of regular food. Many screens have already been
successfully performed in D. melanogaster using food supplementation. For example, 88
chemotherapeutic compounds were tested for their effect on intestinal stem cells in D.
melanogaster (Markstein et al., 2014). In another example, D. melanogaster was used in a screen
of 2,000 compounds for their effect on a model of Fragile X Syndrome (Chang et al., 2008). A
screen utilizing food supplementation with D. melanogaster is highly cost effective, requiring
small amounts of compounds relative to larger model organisms like mice.

Thus, food

supplementation in D. melanogaster represents an efficient and effective way to deliver
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compounds in a screen using our model. Taken together, D. melanogaster is exceptionally well
suited for our proposed plan to induce uric acid kidney stone formation by knocking down urate
oxidase using RNAi and supplementing purines to the diet.
As previously stated, functional urate oxidase is expressed in D. melanogaster while
humans have a so-called pseudogene which is not expressed (Kratzer et al., 2014; Oda et al.,
2002). Loss of urate oxidase expression and enzymatic activity have given way to massive
elevation of uric acid in the serum from 0.4 to 0.7 mg/dl, as seen in many lower apes, to about 4
to 5 mg/dl currently observed in the average American (Johnson et al., 2005). This elevation of
uric acid is problematic considering elevated uric acid can lead to gout and uric acid kidney
stones. To compound the problem in addressing uric acid kidney stone disease, there currently
are no viable or robust animal models of uric acid kidney stone disease.
Our overall goal is to address the lack of a disease model for human uric acid kidney
stone disease. To accomplish this goal, we will develop a translational model of uric acid kidney
stone disease in D. melanogaster by knocking down urate oxidase using RNAi in combination
with dietary purine supplementation. We will then confirm the model forms uric acid kidney
stones. Will urate oxidase knockdown in combination with dietary purine supplementation
elevate uric acid levels and induce the formation of uric acid kidney stones in D. melanogaster?
We hypothesize that if urate oxidase enzyme activity and dietary purine both play critical roles in
uric acid kidney stone formation across species, then knocking down urate oxidase in
combination with dietary purine supplementation will increase uric acid and uric acid kidney
stone formation in D. melanogaster. We can measure uric acid levels using a colorimetric assay.
We can then quantify the percentage of flies that formed uric acid kidney by dissecting the
excretory system of D. melanogaster and visually checking for the presence or absence of uric
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acid kidney stones in a binomial manner for each individual fly. We then calculated the average
probability of forming uric acid kidney stone for each experimental condition.
If knocking down urate oxidase in combination with dietary purine supplementation is
shown to increase uric acid kidney stone formation— can compounds currently used to treat gout
and uric acid kidney stones in humans be used to reduce uric acid kidney stone formation when
urate oxidase is knocked down in combination with dietary purine supplementation in our
model? We hypothesize that if our model of uric acid kidney stones disease mimics human
pathology, then supplementing compounds normally used to treat gout and uric acid kidney
stones in humans, should reduce uric acid kidney stone formation when uric acid kidney stone
formation is induced by urate oxidase knockdown and dietary purine supplementation. We can
test this by supplementing allopurinol, a xanthine oxidase inhibitor used to treat gout and uric
acid kidney stones in humans (Akkasilpa et al., 2004; Halabe and Sperling, 1994), and potassium
citrate, a pH alkalizer used to treat uric acid kidney stones in humans (Maalouf, 2014; Sorkhi et
al., 2011), when uric acid kidney stone formation is induced by urate oxidase knockdown in
combination with dietary purine supplementation.
If compounds used to treat gout and uric acid kidney stones in humans are effective at
reducing uric acid kidney stone formation in our model when urate oxidase is knocked down in
combination with dietary purine supplementation— can compounds predicted to reduce gout and
uric acid kidney stones in humans, but are not currently used for such purposes, reduce uric acid
kidney stone formation when urate oxidase is knocked down in combination with dietary purine
supplementation? We can perform this experiment by supplementing purine synthesis inhibitor
methotrexate, diuretic hydrochlorothiazide, and pH alkalizer l-lysine to our model when uric acid
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kidney stone formation is induced by urate oxidase knockdown in combination with dietary
purine supplementation.
Lastly, we want find new compounds for the treatment of uric acid kidney stone disease
using our model in a medium throughput screen. If we generate a model of uric acid kidney stone
disease in D. melanogaster that forms uric acid kidney stones and the phenotype is successfully
rescued using human treatments for gout and uric acid kidney stone as well as treatments
predicted to be effective—can a medium throughput unbiased screen of compounds find
candidate inhibitors of uric acid kidney stone disease. These candidate compounds can be further
tested using the fly model or a yet to be developed murine model of uric acid kidney stone
disease.
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5

Aims

Aim 1:
The first aim of this research is to develop a translational model of uric acid kidney stone
disease in D. melanogaster.

Rationale:
Because both gout and uric acid kidney stone disease are caused by excessive uric acid in
the serum and urine respectively, we began to investigate ways to elevate uric acid and posed the
question—would urate oxidase knockdown in combination with dietary purine supplementation
induce uric acid kidney stone formation in an animal with functional urate oxidase such as D.
melanogaster? If urate oxidase enzyme activity and dietary purine are both critical in the
formation of uric acid kidney stones across species, then urate oxidase knockdown in
combination with dietary purine supplementation should increase uric acid and uric acid kidney
stone formation in D. melanogaster. In addition, previous experiments have shown that RNAi in
conjunction with food supplementation can induce the formation of calcium oxalate kidney
stones in D. melanogaster (Chen et al., 2011; Hirata et al., 2012), attesting to the applicability of
this procedure for modeling uric acid kidney stone disease.

Hypothesis:
If urate oxidase enzyme activity and dietary purine are both critical in the formation of
uric acid kidney stones across species, then urate oxidase knockdown in combination with
dietary purine supplementation should increase uric acid and uric acid kidney stone formation in
D. melanogaster.
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Aim 2:
The second aim will be to test compounds currently used to treat gout and uric acid
kidney stones in humans for their ability to reduce uric acid kidney stone formation in our model
when uric acid kidney stone formation is induced by urate oxidase knockdown in combination
with dietary purine supplementation. Compounds used to treat gout and uric acid kidney stones
in humans should also be effective in our model if our model is translational and recapitulates
human uric acid kidney disease.

Rationale:
If urate oxidase knockdown in combination with dietary purine supplementation is shown
to induce uric acid kidney stone formation in D. melanogaster, the question arises whether
compounds used to treat gout and uric acid kidney stones in humans can also reduce uric acid
kidney stone formation in our model. We chose allopurinol and potassium citrate as two
compounds to test. Allopurinol is used to treat human gout and uric acid kidney stones and
works by lowering uric acid levels in the serum and urine through inhibition of xanthine oxidase,
the enzyme that converts xanthine into uric acid (Akkasilpa et al., 2004; Eger et al., 2000; Halabe
and Sperling, 1994; Sriranganathan et al., 2014). Potassium citrate is used to treat human uric
acid kidney stones and works by alkalizing the urine pH and driving the formation of more
soluble urate in urine (Maalouf, 2014; Sorkhi et al., 2011). Both these compounds work in
treating human uric acid kidney stone disease and should work in our model if our model is
translational and recapitulates human disease pathologies. This will initially help validate that
our model conforms and responds as expected to treatments used in humans.
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Hypothesis
If our model of uric acid kidney stone disease in D. melanogaster recapitulates human
pathology and is translational, then supplementing allopurinol or potassium citrate in our model
when urate oxidase is knocked down and dietary purine is supplemented should reduce the
formation of uric acid kidney stones.

Aim 3:
The third aim of this research will be to test compounds not currently used to treat gout or
uric acid kidney stone patients, but are predicted to be effective based on current literature.

Rationale:
Can we find new compounds to reduce gout and uric acid kidney stones using our model
based on literature? We chose compounds that we predicted to be effective in treating uric acid
kidney stones in humans based on literature, but which are not currently used for such purposes.
Since gout and uric acid kidney stones are both diseases of excessive level uric acid, an
end product of purine metabolism, a logical question arises. Can a purine synthesis inhibitor
reduce uric acid kidney stone formation in our model when urate oxidase is knocked down and
dietary purine is supplemented to induce uric acid kidney stone formation? We chose to test,
methotrexate (MTX), an inhibitor of de novo purine synthesis, which works by inhibiting
dihydrofolate reductase during the essential conversion of dihydrofolate to active
tetrahydrofolate for subsequent purine and pyrimidine nucleotide synthesis (Goodsell, 1999;
Rajagopalan et al., 2002; Zhang et al., 2013). If purine synthesis contributes to uric acid kidney
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stone formation when urate oxidase is knocked down and dietary purine is supplemented, purine
synthesis inhibitors should reduce uric acid kidney stone formation in our model.
For the treatment of uric acid kidney stones in humans, it is recommended that patients
stay hydrated to dilute and continuously flush their renal system of small stones (Choi et al.,
2005). Can we supplement diuretics to reduce uric acid kidney stone formation in our model
when urate oxidase is knocked down and dietary purine is supplemented to induce uric acid
kidney stone formation? If diluting and continuously flushing the renal system can prevent uric
acid kidney stone formation in humans, then supplementing diuretics should reduce the
formation of uric acid kidney stones in our model when urate oxidase is knocked down and
dietary purine is supplemented. We choose to test hydrochlorothiazide, a compound that has
been shown to increase urine output in humans (Linton and O'Donnell, 1999) and has been
shown to function in the same manner in the malpighian tubules of D. melanogaster (Linton and
O'Donnell, 1999).
Lastly, we chose to test basic amino l-lysine (L-Lys) to see if we could reduce the
formation of uric acid kidney stones by alkalizing the blood and urine pH. In humans, pH
alkalization is an effective way to reduce uric acid kidney stones using potassium citrate
(Maalouf, 2014; Sorkhi et al., 2011). Can, l-lysine, a basic amino acid, also reduce uric acid
kidney stone formation in our model when urate oxidase is knocked down and dietary purine
supplemented? If uric acid kidney stones formation can be reduced in humans by pH alkalizers,
then supplementing l-lysine when urate oxidase is knocked down and dietary purine is
supplemented should reduce uric acid kidney stone formation. Alkalizers effectively cause the
formation of more soluble urate while reducing the levels of uric acid by increasing the pH above
the pKa1=5.7 of uric acid (Fig. 7).
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Hypothesis:
If purine synthesis contributes to uric acid kidney stone formation when urate oxidase is
knocked down and dietary purine supplemented, then supplementing a purine synthesis inhibitor
like methotrexate should reduce uric acid kidney stone formation in our model.
If diluting and continuously flushing the renal system can prevent uric acid kidney stones
in humans, then supplementing a diuretic like hydrochlorothiazide should reduce the formation
of uric acid kidney stones in our model when urate oxidase is knocked down and dietary purine
supplemented.
If uric acid kidney stone formation can be reduced by a pH alkalizer like potassium
citrate in humans, then supplementing l-lysine, a basic amino acid, to our model when urate
oxidase is knocked down and dietary purine is supplemented, should reduce uric acid kidney
stone formation.

Aim 4:
The fourth aim of this research will be to use our validated D. melanogaster model of
uric acid kidney stone disease to perform a medium throughput screen on 117 natural compounds
for inhibitors of uric acid kidney stone formation.

Rationale:
After generating and validating our model by completing aim 1, aim 2, and aim 3, we
will perform a medium throughput unbiased screen to find candidate compounds that can inhibit
uric acid kidney stone formation. These candidate hits can be further tested to determine whether
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their effect can be recapitulated in our fly model or another organism like mice. If our model
recapitulates uric acid kidney stone disease as seen in humans and this model is validated by
testing (aims 1-4), then a medium throughput screen for compounds to reduce uric acid kidney
stone formation in an unbiased fashion should produce inhibitors of uric acid kidney stone
formation. We chose a 117 natural compound library provided by the Nation Institute of Health
for research testing to perform the medium throughput screen.

Hypothesis:
If our D. melanogaster model of uric acid kidney stone is authentic and compounds
effective in treating human uric acid kidney stones are effective in reducing the formation of uric
acid kidney stones, then a medium throughput 117 compound screen of natural compounds
should provide us with a candidate inhibitor compounds that can reduce uric acid kidney stone
formation.
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6

Materials

6.1 D. melanogaster husbandry
Fly lines were maintained in 25 mm diameter x 95 mm length vials (Genesee, San Diego,
CA, USA, 32-109RL) on stock food under standard conditions of 25 °C and 60% humidity on a
12 h light/dark cycle. When two lines were crossed, females from the driver line (who have
hatched from their pupae less than 7 d prior) were placed into bottles (Genesee Scientific, #49100) with males from the RNAi line (15 females:3 male) 14 d prior to 0 d (-14 d). Driver line
females and RNAi line males were allowed to mate for 7 d and removed from the bottles at 7 d
prior to 0 d (-7 d). Progeny were allowed to develop in the bottles for 7 d and female flies are
sorted onto appropriate food conditions 7 d later (0 d).

6.2 Stock food for D. melanogaster
Stock food was composed of 1.5% SAF Instant Yeast (USA Emergency Supply, Colfax,
North Carolina, USA, N016), 8.5% corn (Genesee Scientific, #62-101), 5% sugar (C&H
Granulated Sugar, Crockett, CA, USA, 50 lbs), 0.46% agar (Genesee Scientific, #16-104) and
85% water by volume. 1% by volume mixture consisting of 41% proprionic acid (Fisher
Scientific, Waltham, MA, USA, A242-212), 0.41% phosphoric acid (Sigma-Aldrich, St. Louis,
MO, USA, P1386-1L), and 54.05% water was added to the food and mixed thoroughly. 75 ml of
stock food was poured into 8 oz fly bottles (Genesee Scientific, #32-129F) and sealed with caps
(Genesee Scientific, #49-100) and allowed to cool to room temperature.
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6.3 Low-Purine (LP) and High Purine (HP) food
Low purine (LP) food was composed of 0.5% Bacto yeast extract (VWR, Radnor, PA,
USA, #90000-722), 8.5% corn (Genesee Scientific, #62-101), 5% sugar (C&H Granulated
Sugar), 0.46% agar (Genesee Scientific, #16-104) and 85% water by volume. High purine (HP)
food was composed of 5% yeast extract, 8.5% corn, 5% sugar, 0.46% agar and 85% water by
volume. The original yeast extract contains 4.9% purines by mass as calculated from information
contained in the manufactures brochure (Table 1), and therefore LP food was 0.5% x 4.9% =
0.0245% by mass purines and HP food was 5% x 4.9% = 0.245% purines by mass purines, a 10
fold difference. For both types of food, the ingredients were mixed and brought to a boil. 1% by
volume of a mixture consisting of 41% proprionic acid (Fisher Scientific, A242-212), 0.41%
phosphoric acid (Sigma-Aldrich, P1386-1L), and 54.05% water was added to the food and mixed
thoroughly. The 3-5 ml of the mixture was poured into fly vials (Genesee Scientific, #49-102)
and cooled too room temperature.

6.4 GS food: LP (-/+) and HP (-/+)
GS food was made by adding a 0.34% by volume mixture of 58 mM mifepristone
(Cayman Chemical, Ann Arbor, MI, USA, #10006317), a progesterone analog, dissolved in
ethanol (95%). Mifepristone was added during the cooling period to make LP (+) or HP (+) food.
Control LP (-) or HP (-) food contains 0.34% by volume of ethanol (95%) instead of
mifepristone. The remainder of the cooking processes was identical to the procedure for making
LP and HP food.
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6.5 Compound supplemented Food:
LP, HP, LP (-/+) and HP (-/+) food can have additional compounds supplemented to the
mixture. Compounds were dissolved in water along with other components of the food mixture.
The remainder of the cooking processes was identical to the procedure for making LP and HP
food.

6.6 HP (+) Diet Supplemented with Synthetic Purine Food
The HP (+) diet supplemented with synthetic purine food is composed of the HP (+) diet
supplemented with 10 mM Adenine (Sigma Aldrich, A8626-25G) and 10 mM Guanine (Sigma
Aldrich, G11950-100G).

7

Methods

7.1 Fly Lines
UO RNAi Line
The Urate Oxidase RNAi line contains homozygous RNAi constructs against urate
oxidase mRNA on the 2nd chromosome downstream of the Gal4-UAS. The line was acquired
from the Japanese National Institute of Genetics (JNIG, 2002). The RNAi sequence (7171R-1) is
contained on the left arm of the 2nd chromosome between 7,775.4 KPB – 7,785.4 KPB (Fig. 10).
The RNAi sequence binds to the target exon sequence of the urate oxidase (Uro-RA) mRNA at
the 5’end, which causes enzymatic degradation of mRNA transcription and knock down of urate
oxidase expression in our model (Fig. 10).
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DaGS Driver Line
The DaGS driver line contains homozygous GS Gal4 transcription factors downstream of
Da protein promoters. The GS Gal4 transcription factor is expressed in the same spatiotemporal
pattern as Gal4 transcription factors in Da driver lines, but requires progesterone or a
progesterone analog binding to activate UAS binding and promote expression of downstream
sequences. Fly strain was acquired from the Benz Lab at Caltech Institute of Technology,
Pasadena, CA.

7.2 qRT - PCR

7.2.1

RNA sample extraction
All steps were performed at room temperature unless otherwise stated using a Quick-

RNA MiniPrep kit (Zymo Research, Irvine, CA, USA, #R1055). For each sample, 10 flies per
condition were placed in a 1.5 ml Eppendorf tubes and 200 µl of RNA Lysis Buffer (Zymo
Research, #R1055) was added and the mixture was homogenized using a pellet pestle (Kimble
Chase Kontes, Vineland, New Jersey, USA, 749540-0000) and homogenizer (Kimble Chase
Kontes, 749540-0000). An additional 400 µl of RNA Lysis Buffer (Zymo Research, #R1055)
was added and the sample was centrifuged at 10,000 rpm for 1 min. 400 µl of supernatant was
transferred to Spin-away Filter (Zymo Research, #R1055) in a collection tube and centrifuged at
10,000 rpm for 1 min. Flow through was collected, and 400 µl of ethanol (95%) was added and
mixed with the sample. The entire sample mixture was transferred to a Zymo-Spin IIICG
Column (Zymo Research, #R1055) and centrifuged at 10,000 rpm for 1 min and flow through
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discarded. 400 µl of RNA Prep Buffer was added (Zymo Research, #R1055) and the samples
were then centrifuged at 10,000 rpm for 30 s and flow through was discarded. 700 µl of RNA
Wash Buffer (Zymo Research, #R1055) had ethanol added (according to the directions on the
packaging) to each sample and centrifuged at 10,000 rpm for 30 s and flow through was
discarded. Another 400 µl of RNA Wash Buffer (Zymo Research, #R1055) with ethanol was
added and samples were centrifuged at 10,000 rpm for 2 min and flow through discarded. A
Zymo-SpinIIICG Column (Zymo Research, #R1055) was placed in an RNAse-free 1.5 ml
Eppendorf tube and 30 µl of DNAse/RNAse-free water was added. The sample was then
centrifuged at 16,000 rpm for 30 s and flow through collected. The OD260/280 was measured with
a Nanodrop (Thermal Scientific, Waltham, MA, USA, 1000-UV/Vis) and diluted with RNAse
free water to obtain a 1 µg / 1 µl of purified RNA.

7.2.2

RT-PCR
All preparation steps were performed on ice unless otherwise stated using a QuantiTect

Kit (Qiagen, Venlo, Netherlands, 205313). 2 µl of 7x gDNA Wipeout Buffer (Qiagen, 205313)
was added to 1 µl of 1 µg / 1 µl purified RNA plus 11 µl of DNAse / RNAse-free water in a PCR
tube plate (Thermoscientific, Waltham, MA, USA, 3418) and incubated for 2 min at 42 °C in
T100 Thermal Cycle (Biorad, Hercules, CA, USA, #186-1096) to eliminate genomic DNA. 6µl
of a 1:4:1 mixture of Quantiscript RT (Qiagen, 205313), 5x Quantiscript RT Buffer (Qiagen,
205313), and RT primer mix of forward and reverse primers for urate oxidase and Tubulin 56D
RA loading control. The mixture was incubated for, 15-30 min at 42°C, then 3 min at 95 °C
using a T100 Thermal Cycle (Biorad, #186-1096), to obtain the final cDNA product of target
transcripts (Fig. 9).
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7.2.3

qRT-PCR
All steps were performed on ice unless otherwise stated using a SensiFast Sybr Kit

(Bioline, London, UK, BIO-98020). Forward and reverse primers were diluted to 500 nM in
RNAse-free water and No-ROX Sybr-Mix (Bioline, BIO-98020) were added to create a 5:2
master mix solution. 7 µl of the master mix was added to wells of a qRT-PCR plate (4titude,
Surrey, UK, 4ti-0383) that contained 3 µl of diluted cDNA. The plate was sealed with
accompanying foil (4titude, 4ti-0500). The plate was then spun shortly to 500 rpm and inserted
into a LightCycler 480 (Roche, Panzberg, Upper Bavaria, Germany, 05015243001) and the
fluorescence was measured. The sample was subjected to one denature cycle to 95 °C at 4.8 °C/s
then a hold for 2 min. This was followed by 40 cycles between 60 °C (20 s hold) and 95 °C (5 s
hold) for template amplification and qRT-PCR fluorescence measurement. The fluorescence
measurement and calculation of amplification curve and Ct was analyzed with LightCycler 480
Software Version 1.5 provided by the manufacturer. ∆Ct values were then normalized to Tubulin
56D RA controls. ∆∆Ct values where calculated relative to experimental controls and given as a
percentage from procedure underlined in a previous study (Schmittgen and Livak, 2008).

7.3 Colorimetric uric acid measurement
The Colorimetric uric acid measurement was performed using a BioVision Uric Acid
Colorimetric Assay Kit (BioVision, Milpitas, CA, USA, K608-100). Uric Acid Probe was
warmed to 37 °C for 2 min and mixed well. 200 µl of Uric Acid Assay Buffer was dissolved
with Uric Acid Enzyme provided with the kit to make a Uric Acid Enzyme Mix. A master mix
solution was made from Uric Acid Buffer, Uric Acid Probe, and Uric Acid Enzyme Mix in a
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48:1:1 ratio. A sample of 5 flies per experimental condition was weighed and averaged to obtain
an average mass per fly to normalize the final uric acid measurement. The flies were then
homogenized in 1.5 ml Eppendorph tubes using a pellet pestle (Kimble Chase Kontes, 7495200090) and homogenizer (Kimble Chase Kontes, 749540-0000) in 200 µl of Uric Acid Assay
buffer for 45 s. The sample was then spun for 60 s at 10,000 rpm to form a pellet. 25 µl of
supernatant was brought to 3 appropriate wells of a 96 well plate (Corning, Corning, NY, USA,
#353916) for a total of 3 technical replicates per condition. 25 µl of Uric Acid Buffer was
brought to each well. 50 µl of master mix was added per well and mixed gently to avoid air
bubbles. At the same time, Uric Acid Standard Concentrations were created from Uric Acid
Standard and Uric Acid Assay Buffer over 6 concentrations of uric acid (0.00 µg, 6.72 µg, 13.44
µg, 26.88 µg, 40.34 µg, and 53.79 µg). The 96-well plate was then covered in aluminum foil and
incubated for 30 min at 37 °C. Colorimetric measurement was then performed using a
fluorescence detection machine at OD570 (Molecular Devices, Sunnyvale, CA, USA, M2). Linear
regression was performed in Excel (Microsoft, Redmond, WA, USA, Excel 2013) using the Uric
Acid Standard Concentration measurements. R2 = 0.9983. Uric acid concentration was then
calculated from the linear equation of the best fit line. The uric acid concentration was then
divided by the average weight of the original 5 flies per condition to normalize the final reading
for differences in mass.

7.4 Micro-dissection of D. melanogaster excretory system
A fly was incapacitated using CO2 gas and placed on a slide next to a droplet of water
under a stereomicroscope (Zeiss, Jena, Germany, STEMI 2000-C). Under the stereomicroscope,
forceps were used to hold down the thorax and grasp the anal plate. Slowly, the forceps were
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used to separate the anal plate with gut and malpighian tubules attached from the fly abdominal
cavity and into the droplet of water. The entire gut with malpighian tubules attached was
completely excised from the fly and checked for uric acid stones concretions. This dissection
protocol was adapted from a previous study (Tauc et al., 2014).

7.5 Uric acid kidney stone formation
Uric acid kidney stone formation was measured in a binomial manner for each individual
fly and any stone(s) larger than 25 µm was counted as one and the absence of a stone or stones
was counted as a zero for each respective fly. The % of stone formers was calculated as the
number of flies that formed uric acid kidney stones divided by the total number per condition.

7.6 Medium throughput screen of 117 natural compounds
The HP (+) diet supplemented with synthetic purine food was cooked according to the
corresponding protocol in the materials section and poured into 96-well plates (VWR, 15705066) with 1 mm holes in the center of each well. The 96-well plates (VWR, 15705-066) were put
on top of 1 ml 96-well masterblocks (VWR, 82051-244) and centrifuged at 4,000 rpm for 2 min
and the food was allowed to cool for 3 h. 10 µl of each compound (200 µM) in dimethyl
sulfoxide (1:50) (Alfa Aesar, Ward Hill, MA, USA, 43998) solution was administered on top of
the HP (+) diet supplemented with synthetic purine food in each well of the 1 ml 96-well
masterblocks (VWR, 82051-244)

accordingly. The reference diet was the HP (+) diet

supplemented with synthetic purine food topped with 10 µl of dimethyl sulfoxide (1:50) solution
(Alfa Aesar, 43998) and the positive control was the HP (+) diet supplemented with synthetic
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purine food topped with 10 µl of methotrexate (200 µM) (Sigma Aldrich, PHR1396-1G). The 1
ml 96-well masterblocks (VWR, 82051-244) were then centrifuged at 4,000 rpm for 2 min and
the solutions delivered on top of the food are allowed to absorb into surface of the for 3 h. For
the screen, there were 3 wells per condition and 5 flies per well were place into each well. The
top of the 1 ml 96-well masterblocks (VWR, 82051-244) were covered with 96-well plates with
200 µm air holes and sealed with tape. Flies are housed at 29 °C and 60% humidity on a 12 h
light/dark cycle. Every other day, flies are transferred from the old 1 ml 96-well masterblocks
(VWR, 82051-244) into a new 1 ml 96-well masterblocks (VWR, 82051-244) with fresh
compound solutions. Flies are dissected after 7 d.
The 117 compounds came from the natural compound products set III provided by the
Developmental Therapeutics Program of the National Institute of Health (NTP, 2015).

7.7 Statistics
Student’s two-tailed t-test analysis was performed as paired samples. *** = p-value <
0.001, ** = p-value < 0.01, * = p-value < 0.05. Confidence Intervals (CI) are calculated as 95%.
Standard error of the mean is abbreviated SEM. All calculations were computed using Prism
4.03 Software (Muzyka et al., 1992-2005).
One-way analysis of variance (ANOVA) was performed as repeated measures and
Tukey’s multiple comparison tests were performed. *** = p – value < 0.0005, ** = p – value <
0.01, * = p – value < 0.05. Confidence intervals are calculated as 95%. All calculations were
computed using Prism 4.03 software (Graphpad Software Inc, La Jolla, CA, USA).
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8

Results

8.1 Efficient urate oxidase knockdown in D. melanogaster using RNAi
We first wanted to confirm that we had efficient knockdown of urate oxidase in our
model using RNAi, therefore we performed qRT-PCR on urate oxidase mRNA in Da > UO
RNAi (urate oxidase knockdown) flies and Da > W1118 (control) flies fed the stock diet at 0 d.
We observed that there was efficient knockdown of urate oxidase at 0 d and a significant
decrease in urate oxidase mRNA transcripts over 11 biological replicates (Fig. 11A). At 0 d,
urate oxidase mRNA in our urate oxidase knockdown flies was at 10% relative to control flies
(Fig. 11A) and this knockdown was significant (p < 0.001). When we compared the ∆Ct value of
urate oxidase knockdown flies relative to control flies, we observed that there was a significant
reduction in urate oxidase mRNA (higher ∆Ct value) at 0 d over 11 biological replicates (Fig.
11B). To be specific, the ∆Ct value for urate oxidase knockdown flies substantially increased
from 3.88 to 7.06 (Fig. 11B) and this increase was significant (p < 0.001).
Next, we wanted to see if urate oxidase knockdown remained efficient throughout
adulthood and what effect dietary purine may have on urate oxidase expression, therefore we
performed qRT-PCR on urate oxidase mRNA in Da > UO RNAi (urate oxidase knockdown)
flies fed the LP and HP diets for 7 and 14 d (Fig. 11C). The LP food was 0.5% x 4.9% =
0.0245% by mass purines and the HP food was 5% x 4.9% = 0.245% purines by mass purines,
which means the HP diet had 10 times more purines by mass than the LP diet. We observed
knockdown of urate oxidase at 7 d on the LP diet but this knockdown was less efficient on the
HP diet (Fig. 11C). This pattern was observed also at 14 d (Fig. 11C). At day 7, the relative
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levels of urate oxidase mRNA in our urate oxidase knockdown flies were at 8% and 13% on the
LP and HP diets compared to control flies respectively (Fig. 11C). At day 14, the relative levels
of urate oxidase mRNA in our urate oxidase knockdown flies were at 15% and 36% on the LP
and HP diets respectively compared to the control flies (Fig. 11C). Though only one biological
replicate was performed, the consistent knockdown of urate oxidase over both the LP and HP
diets at 7 and 14 d strongly suggests that our knockdown of urate oxidase was efficient and
persisted throughout adulthood. Furthermore, urate oxidase expression appears to be upregulated
when dietary purine was supplemented at both 7 and 14 d despite urate oxidase knockdown by
RNAi.

8.2 Urate oxidase knockdown and dietary purine supplementation in D.
melanogaster increased uric acid levels
After initially confirming that our urate oxidase knockdown was efficient, we then
wanted to test if urate oxidase knockdown and dietary purine supplementation could increase
uric acid levels. It is already known that reducing purine intake can effectively reduce uric acid
and uric acid kidney stone formation in humans (Choi et al., 2005; Halabe and Sperling, 1994).
To test if urate oxidase knockdown and dietary purine supplementation can increase uric acid
levels in our model, we performed a colorimetric assay for uric acid in DaGS > UO RNAi (urate
oxidase knockdown flies) fed the LP and HP diets with and without RNAi expression activator
mifepristone (progesterone analog) after 7 and 14 d (Fig. 12). We observed that uric acid
increased when urate oxidase was knocked down on the HP (+) diet compared to the LP (+) diet
at 7 and 14 d (Fig. 12). On our control LP (-) and HP (-) diet, there was no activation of urate
oxidase knockdown and dietary purine supplementation did not increase uric acid levels at 7 or
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14 d compared to the LP (+) and HP (+) diets (Fig. 12). After 7 d, in control flies fed the LP (-)
and HP (-) control diets compared to urate oxidase knockdown flies fed the LP (+) and HP (+)
diets, uric acid was elevated and jumped from 50.3 µM to 54.7 µM (p > 0.05) and 67.3 µM to
68.33 µM respectively (p > 0.05) (Fig. 12). After 14 d, uric acid levels increased from 54.3 µM
to 55.7 µM for the LP (-) diet compared to the LP (+) diet. For the HP (-) diet compared to HP
(+) diet after 14 d, uric acid significantly increased from 88 µM to 155 µM (p < 0.001). In the
control flies and urate oxidase knockdown flies, the HP diet tended to elevated uric acid levels
regardless of whether urate oxidase was knocked down (Fig. 12). However, when urate oxidase
was knocked down and dietary purine supplemented, elevation of uric acid was higher
comparing the HP (-) and HP (+) diet at 14 d (Fig. 12). Strikingly, uric acid elevation appears to
be time dependent and increases with age when we compare the uric acid levels at 7 d and 14 d
(Fig. 12). Furthermore, urate oxidase knockdown further pushed uric acid levels higher relative
to control flies (Fig. 12). These initial findings suggested that in our model, urate oxidase
knockdown and dietary purine supplementation increased uric acid levels as we hypothesized.
We further validated that urate oxidase knockdown and dietary purine supplementation increased
uric acid levels by having collaborators perform LC/MS/MS to measure global levels of uric acid
as well other important purine metabolites like adenine, adenosine, guanine, guanosine, and
xanthine. When LC/MS/MS was performed, we saw that DaGS > UO RNAi (urate oxidase
knockdown) flies fed the HP (+) diet had a four-fold increase in uric acid levels relative to uric
oxidase knockdown flies fed the control HP (-) diet (data not shown). In parallel, allantoin
decreased 1 order of magnitude also as expected while adenine, adenosine, guanine, and
guanosine remained stable (data not shown).
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8.3 Urate oxidase knockdown and dietary purine supplementation in D.
melanogaster increased uric acid kidney stone formation
Next we wanted test if elevation of uric acid by urate oxidase knockdown and dietary
purine supplementation can induced the formation of uric acid kidney stones. We performed
micro-dissection and measured uric acid kidney stone formation in DaGS > UO RNAi (urate
oxidase knockdown) flies fed the LP (+) and HP (+) diets and control flies fed the LP (-) and HP
(-) control diets after 14 d in 3 separate biological trials (Fig. 13A). When dietary purines was
supplemented and urate oxidase knocked down, the formation of uric acid kidney stones
increased significantly for flies on the HP (+) diet compared to control flies fed the HP (-)
control diet and uric acid kidney stone formation jumped from 8% to 72% (p < 0.001) (Fig.
13A). We took samples images of DaGS > UO RNAi (urate oxidase knockdown) flies fed the
HP (+) diet and compared them to control flies fed the HP (-) control diet (Fig. 13C). From the
pictures, the appearance of large concretions and mineralized structures can be observed visually
(Fig. 13C). On the LP (-/+) diet, dietary purine supplementation in combination with urate
oxidase knockdown did not induce uric acid kidney stone formation for either group, which
remained at 0% (Fig. 13A). Next, we wanted to test if urate oxidase knockdown during
development and during adulthood could also induce uric acid kidney stones when dietary
purines were supplemented in adulthood using the Da driver. We performed micro-dissection
and measured uric acid kidney stone formation in Da > UO RNAi (urate oxidase knockdown)
flies and Da > W1118 (control) flies fed the LP and HP diet after 14 d in 3 separate biological
trials (Fig. 13B). When purines were supplemented in adulthood and urate oxidase knocked
down during development and adulthood, the formation of uric acid kidney stones increased
significantly for flies on the HP diet compared to control flies fed the LP diet, which jumped
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from 0% to 50% (p < 0.01) (Fig. 13B). On the LP diet, urate oxidase knockdown did not
increase uric acid kidney stone formation, which remained at 0% (Fig. 13B). Using two different
drivers, we saw that regardless of when urate oxidase was knocked down, whether that was
during adulthood or development and adulthood, urate oxidase knockdown and dietary purine
supplementation induced uric acid kidney stones to form in our model of uric acid kidney stone
disease.

8.4 Allopurinol and potassium citrate reduced uric acid kidney stone formation in
our D. melanogaster model of uric acid kidney stone disease
After initially confirming that urate oxidase knockdown in combination with purine
supplementation could elevate uric acid and induce the formation of uric acid kidney stones, we
wanted to test if we could reduce uric acid kidney stone formation in our model using
compounds currently utilized in the treatment of gout and uric acid kidney stone patients.
We first tested allopurinol, a compound used for the treatment of gout and uric acid
kidney stones in humans (Akkasilpa et al., 2004; Halabe and Sperling, 1994). Allopurinol
inhibits xanthine dehydrogenase, the enzyme that converts xanthine into uric acid, which reduces
uric acid levels and uric acid kidney stone formation in humans (Elion et al., 1966; Halabe and
Sperling, 1994; Sriranganathan et al., 2014). We performed micro-dissection and measured uric
acid kidney stone formation in Da > UO RNAi (urate oxidase knockdown) flies fed the HP diet
with and without allopurinol (10 mM) (Fig. 14A). We observed that allopurinol (10mM)
significantly reduced uric acid kidney stone formation from 64% to 25% (p < 0.05) (Fig. 14A).
To further confirm allopurinol was effective at reducing uric acid kidney stones, and could
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reduce uric acid kidney stone formation even when urate oxidase was knocked downed during
adulthood but not development, we then performed micro-dissection and measured uric acid
kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet
with and without allopurinol (10 mM) (Fig. 14B). Allopurinol significantly reduced uric acid
kidney stone formation from 64% to 19% when we compared flies fed the HP (+) diet to the HP
(+) diet supplemented with allopurinol (p < 0.05) (Fig. 14B).
We next tested potassium citrate, a pH alkalizer used to treat cystine kidney stones and
uric acid kidney stones in humans (Sorkhi et al., 2011), to test if the compound was also effective
at reducing uric acid kidney stone formation in our model. We performed micro-dissection and
measured uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies
fed the HP (+) diet with and without potassium citrate (200mM) (Fig. 14C). We observed a
significant reduction of uric acid kidney stone formation from 56% to 3% when we compared
flies fed the HP (+) diet to flies fed the HP (+) diet supplemented with potassium citrate (p <
0.001) (Fig. 14C). To test whether potassium citrate can reduce uric acid kidney stone formation
in a dose dependent manner, we me supplemented 10, 50, 100, and 200 mM of potassium citrate
to the HP (+) diet and measured uric acid kidney stone formation (Fig. 14D). We observed that
potassium citrate reduced uric acid kidney stone formation to 35%, 21%, 14%, and 0.0% when
10, 50, 100, and 200 mM of potassium citrate was supplemented to the diet HP (+) diet
respectively (Fig. 14D). The trend showed a dose dependent reduction in uric acid kidney stone
formation when potassium citrate was supplemented (Fig. 14D). Potassium citrate reduced uric
acid kidney stone formation to almost 0% when 200 mM was supplemented over three
experimental trials (n=3) (Fig. 14C) and an additional trial in a single separate experiment (n=1)
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(Fig 14D), which argues for the effectiveness of potassium citrate as in treating uric acid kidney
stones in our model.

8.5 Compounds predicted to be effective against uric acid kidney stones formation;
methotrexate, hydrochlorothiazide, and l-lysine reduced uric acid kidney stone
formation in our model
We saw that compounds used to treat gout and uric acid kidney stones in humans were
effective at reducing uric acid kidney stone formation when urate oxidase was knocked down
and dietary purine supplemented in our model. Next we wanted to test if compounds predicted to
reduce uric acid kidney stone formation from the literature, could reduce uric acid kidney stone
formation in our model when urate oxidase was knocked down and dietary purine supplemented.
We chose methotrexate, a de novo purine synthesis inhibitor (Goodsell, 1999; Rajagopalan et al.,
2002). We performed micro-dissection and measured uric acid kidney stone formation in DaGS
> UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet without and with methotrexate
(5, 50, and 500 µM) supplemented (Fig. 15A). Supplementing 5, 50, and 500 µM of
methotrexate to our urate oxidase knockdown flies supplemented dietary purines, significantly
reduced uric acid kidney stone formation from 64% to 17%, 6%, and 0% respectively (Fig. 15A).
At the highest concentration of 500 µM, methotrexate significantly reduced uric acid kidney
stone formation to 0% (p < 0.001) (Fig. 15A).
L-lysine was also effective at reducing uric acid kidney stone formation (Fig. 15A).
When micro-dissection was performed and uric acid kidney stone formation measured in DaGS
> UO RNAi (urate oxidase knockdown) flies, uric acid kidney stone formation was moderately
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reduced from 64% to 44%, 30%, and 17% when 10 µM, 100 µM, and 1000 µM of l-lysine was
supplemented to the HP (+) diet respectively (Fig. 15A). At the highest concentration of 1000
µM, l-lysine significantly reduced uric acid kidney stone formation to 17% (p < 0.001) (Fig.
15A). Similarly, hydrochlorothiazide was also effective at reducing uric acid kidney stone
formation from 64% to 47%, 39%, and 31% when 10, 100, and 1000 µM of hydrochlorothiazide
were supplemented to the HP (+) diet respectively (Fig. 15A). At the highest concentration of
1000 µM, hydrochlorothiazide significantly reduced uric acid kidney stone formation to 31% (p
< 0.001) (Fig. 15A).
Of the three compounds tested, the most effective at reducing uric acid kidney stone
formation was methotrexate (Fig. 15A). We wanted to further test our strongest candidate
compound, methotrexate, therefore we then performed micro-dissection and measured uric acid
kidney stone formation in Da > UO RNAi (urate oxidase knockdown) flies fed the LP diet and
the HP diet with and without methotrexate over three different concentrations (5, 50, 500 µM)
and in Da > W1118 (control) flies fed the LP and HP diet after 14 d (Fig. 15B). We observed
that increasing methotrexate concentration reduced uric acid kidney stone formation in a dosage
dependent manner over 3 biological replicates (Fig. 15B). When 5, 50, and 500 µM of
methotrexate was supplemented to the HP (+) diet, uric acid kidney stone formation was
significantly reduced from 50% to 14%, 0%, and 0% respectively (Fig. 15B). At the highest
concentration of 500 µM, methotrexate significantly reduced uric acid kidney stone formation to
0% (p < 0.001) (Fig. 15B). When both experiments are taken together, methotrexate appears to
be an effective and robust compound for reducing uric acid kidney stone formation in our model.
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8.6 Medium throughput compound screen of 117 natural compounds finds 7
inhibitors and 6 enhancers of uric acid kidney stone formation in our D.
melanogaster model of uric acid kidney stone disease
We then performed a medium throughput natural compound screen using compounds
from the Natural Products set III from the Nation Therapeutics Program of the National Institute
of Health. We administered the compounds to DaGS > UO RNAi (urate oxidase knockdown)
flies fed a HP (+) diet supplemented synthetic purines adenine (10 mM) and guanine (10 mM).
We found Uric Acid Kidney Stone Inhibitors (UAKSIs) 1, 2, 3, 4, 5, 6, and 7 and Uric Acid
Kidney Stone Enhancers (UAKSEs) 1, 2, 3, 4, 5, and 6. We categorized inhibitors that reduced
the formation of uric acid kidney stone formation to less than 20% and enhancers that increased
uric acid kidney stone formation to 80% or more. Our urate oxidase knockdown flies fed the
reference HP (+) diet supplemented with synthetic purines and topped with dimethyl sulfoxide
had 72% uric acid kidney stone formation (Fig. 18). Our positive control, knockdown flies fed
the HP (+) diet with synthetic purines topped with methotrexate (200 µM), had 8% uric acid
kidney stone formation (Fig. 18). Methotrexate decreased uric acid kidney stone formation and
this was consistent with previous experiments that showed a robust decrease in uric acid kidney
stone formation when methotrexate was supplemented to urate oxidase knockdown flies fed the
HP diet (Fig. 14-15).
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9

Discussion
The total number of people who suffer from accumulation of uric acid deposits or

elevated uric acid levels is enormous. In the US alone, from 2007-2008, there were a total of 8.3
million patients who suffered from gout (Zhu et al., 2011). The total cost of treating patients with
gout was estimated to be around 7.7 billion dollars for; inpatient and outpatient care, prescription
drugs, emergency room visits, and other costs (Cisternas et al., 2009). The number of patients
who will suffer from uric acid kidney stones at least once in their life in the US is estimated to be
between 1.5 and 4.2 million patients (Bushinsky, 2001; Stamatelou et al., 2003). The probability
of uric acid kidney stones reoccurrence after the first episode increases 23% and each subsequent
episode further increases that probability (Trinchieri et al., 1999b). A very conservative estimate
of the total cost of treating patients who suffer from uric acid kidney stones in the US, is around
300 million dollars annually (Bushinsky, 2001; Campion et al., 1987; Lotan, 2009; Walker et al.,
2013). Taken together, the total number of people affected by accumulation of uric acid deposits
or uric acid kidney stones disease is a staggering 9.8 million and the total cost is an enormous
sum of 8 billion dollars. Finding new and innovative solutions for these patients that are effect
remains a major challenge in urology and healthcare in general.
To compound the problem, there are no viable models of uric acid kidney stone disease in
mice, no model exists in D. melanogaster all together, and uric acid kidney stone has yet to be
modeled in any other model organism, highlighting the need for the development of such a
model. There is a murine urate oxidase knockout model, but the murine model shows high
lethality with 65% of the homozygous mutant mice dying within 4 weeks of birth unless
maintained on allopurinol to reduce the extremely high levels or uric acid in the serum and urine
(Wu et al., 1994). Other types of kidney stones, like cystinuria, have a viable murine model that
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can recapitulate the disease phenotype. For example, a SLC7A9 knockout mouse model was
created that is viable and forms cystinuria kidney stones and this disease phenotype can be
rescued by administration of d-penicillin or mercaptopropionylglycine, also known as tiopronin
(Font-Llitjos et al., 2007). In D. melanogaster, there have been previous work that have
successfully modeled calcium oxalate kidney stones and other kidney stone associated disorders
by using RNAi and food supplementation that showed the possibility of modeling uric acid
kidney stone disease in a similar way (Chen et al., 2011; Hirata et al., 2012; Knauf and Preisig,
2011; Miller et al., 2013). To address the lack of a disease model for uric acid kidney stones, we
successfully created a model of uric acid kidney stone disease in D. melanogaster by using RNAi
and dietary modulation.

9.1 Validation of D. melanogaster model of uric acid kidney stone disease
We validated our model using; qRT-PCR to measure mRNA levels of urate oxidase, a
colorimetric assay to measure uric acid levels, and performed micro-dissection to measure uric
acid kidney stone formation (Fig. 11-13). We first confirmed the efficient knockdown of urate
oxidase in our model using qRT-PCT (Fig. 11). After confirming our knockdown was efficient,
we supplemented our urate oxidase knockdown flies with a high purine diet to induce uric acid
kidney stone formation (Fig. 11-13). If urate oxidase enzyme activity and dietary purine are both
critical in the formation of uric acid kidney stones across species, then urate oxidase knockdown
in combination with dietary purine supplementation should increase uric acid and uric acid
kidney stone formation in D. melanogaster. We saw that our model could be induced to form
uric acid kidney stones when urate oxidase was knocked down and purine supplemented to the
diet (Fig. 11-13). Uric acid levels increased with urate oxidase knockdown and dietary purine
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supplementation and also appeared to increase with age (Fig. 12). Lastly and most importantly,
we visually confirmed, then measured uric acid kidney stone formation and saw that it increased
when uric acid was knocked down and purines supplemented (Fig. 13C). These findings further
reaffirm the role of dietary purine in modulating uric acid levels that was previously seen in
humans (Choi et al., 2005; Halabe and Sperling, 1994; Hediger et al., 2005; Johnson et al.,
2005).

9.2 Testing human gout and uric acid kidney stone treatments using D.
melanogaster model of uric acid kidney stone disease
After initially confirming that urate oxidase knockdown was efficient and dietary purine
supplementation could induce uric acid kidney stone formation (Fig. 11-13). We tested whether
compounds currently used to treat gout and uric acid kidney stones in humans, like allopurinol
and potassium citrate, were also effective at treating uric acid kidney stones in our model (Fig.
14A-C). If our model of uric acid kidney stone disease in D. melanogaster recapitulates human
pathology and is translational, then supplementing allopurinol or potassium citrate in our model
when urate oxidase was knocked down and dietary purine supplemented should reduced the
formation of uric acid kidney stones. We saw that, both allopurinol and potassium citrate were
effective at reducing uric acid kidney stone formation (Fig.14A-D). Allopurinol inhibits xanthine
dehydrogenase, the enzyme that converts xanthine into uric acid (Fig. 16) (Eger et al., 2000), and
is used to treat gout and uric acid kidney stones in humans (Akkasilpa et al., 2004; Halabe and
Sperling, 1994). Therefore, supplementing allopurinol should decrease uric acid levels and
inhibit uric acid kidney stone formation by preventing the conversion of xanthine into uric acid
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(Fig. 16). We observed the predicted reduction in uric acid kidney stone formation when
allopurinol was tested (Fig. 14A-B). When pH alkalizer potassium citrate was tested, the
compound also reduced uric acid kidney stone formation (Fig. 14C-D). Potassium citrate
increases the pH, which drives the formation of more soluble urate and thus reduces uric acid
and uric acid kidney stone formation (Fig. 16). Uric acid kidney stone formation was reduced
when allopurinol or potassium was supplemented to our uric acid kidney stone model (Fig. 14AC), which further substantiates our model as being translation and applicable for modeling
human uric acid kidney stone disease. Given the two compounds are from distinct chemical
classes, and yet are able to reduce uric acid kidney stone formation in humans and in our model
as predicted, it is likely that major core components of human uric acid kidney stone disease are
recapitulated in our D. melanogaster model of uric acid kidney stone disease.

9.3 Testing of compounds predicted to reduce uric acid kidney stone formation
using D. melanogaster model of uric acid kidney stone disease
In the realm of pharmacology, one compound or drug can have multiple off target effects
and the phenomenon is called polypharmacology (Apsel et al., 2008; Hopkins, 2008; Simon et
al., 2011). One of the most famous example is Viagra, a phosphodiesterase inhibitor that was
originally developed to treat ischemic heart disease and hypertension, is now most frequently
used to treat erectile dysfunction (DeBusk et al., 2004). Another example is Aspirin; an analgesic
used to relieve minor aches and pains is also used as a non-steroidal anti-inflammatory drug for
rheumatoid arthritis (Simpson et al., 1966), Kawasaki disease (Durongpisitkul et al., 1995), and
pericarditis (Berman et al., 1981) to name a few.
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With this in mind, we tested known compounds, which are not currently used in the
treatment of gout or uric acid kidney stone disease in humans, like methotrexate,
hydrochlorothiazide, and l-lysine, but are predicted from literature to reduce uric acid kidney
stone formation (Fig. 15A). We observed that methotrexate was most effective at reducing uric
acid kidney stone formation in our model when urate oxidase was knocked down and dietary
purine supplemented (Fig. 15A-B). Methotrexate effectively reduced uric acid kidney stone
formation in a robust manner across different concentrations using two different drivers (Fig.
15A-B). Methotrexate inhibits dihydrofolate reductase in the essential conversion of
dihydrofolate into tetrahydrofolate for purine synthesis and thus should reduce purine load and
uric acid kidney stone formation by reducing the flow of purines through the entire purine
pathway (Fig. 16). Furthermore, methotrexate reduced uric acid kidney stone formation to 0% at
higher concentrations of 50 and 500 µM using both Da and DaGS drivers (Fig. 15A-B).
Hydrochlorothiazide and l-lysine were also effective at reducing uric acid kidney stone formation
in our model when urate oxidase was knocked down and dietary purine supplemented, but was
less potent when compared to methotrexate (Fig. 15A-B). At higher concentrations of 100 and
1000 µM, hydrochlorothiazide and l-lysine could not robustly reduce uric acid kidney stone
formation to 0% as methotrexate could at lower concentrations of 5 and 50 µM (Fig. 15A-B).
Given those results, methotrexate appears to be extremely effective at reducing uric acid kidney
stone formation in our model, and had greater potency compared to other tested compounds like
l-lysine and hydrochlorothiazide.
Hydrochlorothiazide, a diuretic, was shown to reduce uric acid kidney stone in a dose
dependent manner (Fig. 15A). In humans, hydrochlorothiazide works by inhibiting reabsorption
of Na+ from the lumen of distal convoluted tubule by NA+Cl- co-transporter into apical membrane
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cells, which reduces the passive reabsorption of water that follows the non-reabsorbed sodium
into the urine (Fig. 17) (Ali et al., 2012; Ecelbarger and Tiwari, 2006). It has also been shown
that administering mineral water to patients that formed calcium oxalate kidney stones to
increase urine output, decreased the overall occurrence of calcium oxalate kidney stones
(Trinchieri et al., 1999a). One possible explanation may be that increasing urine output also
eliminates small stones and concretions before growth to a size sufficient to block the urinary
tract (Fig. 17). In D. melanogaster, basolateral Na+Cl- co-transporters of the malpighian tubules
have been shown to play a significant role in ion exchange (Linton and O'Donnell, 1999). It is
therefore possible that hydrochlorothiazide reduced uric acid kidney stone formation in our
experiment in a similar manner by increasing urine flow (Fig. 17). A future experiment to
validate this hypothesis could be to knockdown urate oxidase to induce uric acid kidney stone
formation and overexpress of Na+Cl- co-transporters in parallel. Overexpression of Na+Cl- cotransporters should reduce uric acid kidney stone formation. Other hormones that drive water
secretion in flies like Cap2b, kinin, or DH44 can also be used to further test and validate whether
increased urine output can reduce uric acid kidney stones in our model.
L-lysine, a basic amino acid, was also shown to reduce uric acid kidney stone formation
in a dosage dependent manner (Fig. 15A). Currently, urine alkalization is the main treatment
option of choice to reduce uric acid kidney stones formation (Dardamanis, 2013). Given these
facts, one possible explanation for these findings is that l-lysine alkalizes the urine. Higher pH
levels above the pKa1 of uric acid (pKa=5.7) (McCrudden, 2008), causes the formation of more
soluble urate from less soluble uric acid (Fig. 7) (Fig. 16), which decreases the overall level of
uric acid (Fig.16). One possible future experiment to test whether l-lysine is reducing uric acid
kidney stone formation through alkalization would be to feed urate oxidase knockdown flies l-
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lysine and collect the urine to test the pH. Another possible explanation may be that l-lysine,
which is positively charged, surrounds and neutralizes the negatively charged uric acid stones.
We could test this hypothesis by feeding urate oxidase knockdown flies isotope labeled l-lysine
and tracing where the labeled l-lysine accumulates. If l-lysine chelates uric acid kidney stones
and prevents further growth, then isotope labeled l-lysine should accumulate around uric acid
kidney stones in our fly model when uric acid kidney stones formation is induced.
Our most effective compound methotrexate, a compound used for treatment of cancer
and auto immune disease in humans (Goodsell, 1999; Rajagopalan et al., 2002; Wright et al.,
1964), reduced uric acid kidney stone formation to 0% at 50 and 500 µM utilizing both the Da
and DaGS driver (Fig. 15A-B). Methotrexate inhibits purine synthesis by competitively binding
dihydrofolate reductase during the essential conversion of dihydrofolate to active
tetrahydrofolate in the nucleotide synthesis pathway (Fig. 16) (Goodsell, 1999; Rajagopalan et
al., 2002). In contrast, overexpression or hyper activity of the enzyme PRPP synthetase, which
catalyzes the first step of purine synthesis, has the opposite effect of inducing elevated uric acid
levels in the serum (Becker et al., 1986; Fujimori, 1996; Tatibana, 1996; Yamada et al., 2014;
Yamada et al., 2010). These results reaffirm the validity of our model given that inhibition of de
novo purine synthesis is expected to alleviate hyperuricemia and uric acid kidney stones by
reducing the overall flow of purine through metabolism, salvage, degradation, and excretion
(Fig. 16). An interesting experiment would be to measure metabolomic data on major purine
nucleotides and purine metabolites in flies that are induced to form uric acid kidney stones by
urate oxidase knockdown and dietary purine supplementation compared to those same flies
supplemented methotrexate. If the overall flow of purine metabolites through purine metabolism,
salvage, degradation, and excretion decreases, then this trend should be discernible from

54
metabolomic data. Even though methotrexate appears to be an extremely effective compound for
treating uric acid kidney stone disease, the immune suppressant effects of methotrexate are
problematic when treating human patients. Patients who are fighting infections or may encounter
infections are at risk of fatal complications. An alternative compound or compounds that can
reduce uric acid kidney stone formation but does not suppress the immune system is preferable.
However, the model we created will allow us the opportunity to screen for compounds that can
effectively treat uric acid kidney stones but have fewer deleterious effects.

9.4 Medium throughput screen of 117 compounds using D. melanogaster model of
uric acid kidney stone disease finds seven inhibitors and six enhancers.
When we used our D. melanogaster model of uric acid kidney stone disease to screen 117
compounds from the Natural Compound Products Set III provided by the Developmental
Therapeutics Program of the National Institute of Health ((NTP, 2015). We found 7 inhibitors;
UAKSI1, UAKSI2, UAKSI3, UAKSI4, UAKSI5, UAKSI6, and UAKSI7 when we performed
the medium throughput screen (Fig. 18). We also found 6 enhancers; UAKSE1, UAKSE2,
UAKSE3, UAKSE4, UAKSE5, and UAKSE6 when we performed the medium throughput
screen (Fig. 18). No discernible pattern appears from the list of inhibitors and enhancers that
were found during the medium throughput screen (Fig. 18). Anti-tumorgenic compounds appear
to be randomly distributed as inhibitors and enhancers of uric acid kidney stone formation.
Further testing of individual compounds is required to further understand the mechanism by
which uric acid kidney stone formation is reduced in our model for each respective compound.
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9.5 Future experimental plans
In the future, we plan to transfer the results from our D. melanogaster model of uric acid
kidney stone disease to a murine model. The murine model we will pursue would give us another
tool to study uric acid kidney stone disease. Using oxonic acid, an inhibitor of urate oxidase in
mice, we plan to elevate uric acid and recapitulate uric acid kidney stone disease in mice much
like in our fly model. We will then test drugs and compounds for their ability to reduce uric acid
kidney stones using this murine model. First, we will likely test methotrexate and the data and
results should verify and validate findings found in our fly model. We also plan to execute a
larger compound screen with thousands of compounds from the National Institute of Health
using our fly model. By fully developing both a fly and murine model of uric acid kidney stone
disease, we hope to be able to find novel solutions to treat patients who suffer from an
accumulation of uric acid deposits or elevated uric acid levels, which number 9.8 million in the
U.S. alone (Bushinsky, 2001; Stamatelou et al., 2003; Walker et al., 2013).
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11 Tables and Figures
11.1 Tables

Table 1: Bacto yeast extract composition
The composition of Bacto yeast extract from manufactures brochure. Table adapted from (BD-Bioscience, 2006).
Total Nitrogen Amino Nitrogen Amino
Nitrogen/Total
(%)
(%)
Nitrogen
Total Carbohydrate (mg/g)
Yeast
Extract,
Bacto
10.9
6
0.55
163.3

Table 2: Table of Primers Used
The table shown contains forward and reverse primers for UO and β-Tubulin 56D RA. Primers where designed using BLAST
(Altschul et al., 1997).
Forward Primer
Reverse Primer
UO

GCGATGTGGTTATAAGGAGAACA

TCTTCAGCACCCGGAGAC

β-Tubulin 56D RA

AGAAAGCCTTGCGCCTGAACA

ACATCCGGCCCCGTGGTC
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11.2 Figures
Figure 1: Purine Structure
Purine skeleton with numbering pattern for atoms of the fused pyrimidine ring (1
(1-6)
6) and imidazole ring (4-5,
(4
7-9). Picture
adapted from NCBI PubChem Compound Database, CID: 1044 (PubChem, 2015).

Figure 2: Adenine and Guanine Structure
Purines: adenine (left) and guanine (right). Picture adapted from NCBI PubChem Compound Database, CID: 190 & 764
(PubChem, 2015).

Figure 3: ATP Structure
The molecule shown is ATP. Picture adapted from NCBI PubChem Compound Database, CID: 5957 (PubChem, 2015).
2015)
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Figure 4: NADH structure
Picture adapted from NCBI PubChem Compound Database, CID: 439153 (PubChem, 2015).

Figure 5: Xanthine Structure
Picture adapted from NCBI PubChem Compound Database, CID: 1188 (PubChem, 2015).
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Figure 6: Purine degradation pathway in flies and humans (excluding urate oxidase and allantoin)
Pictured is the purine degradation pathway from major metabolic nucleotides AMP, IMP, and GMP to uric acid (Mathews,
1996).

Figure 7: Uric acid and urate anion interconversion
Picture adapted from (Hediger et al., 2005).
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Figure 8: Allantoin structure
Picture adapted from NCBI PubChem Compound Database, CID: 204 (PubChem, 2015).

Figure 9: PCR Targets Transcripts
UO: Urate Oxidase Common Gene 7171 (CG7171) sequence from BLAST database (Altschul et al., 1997).
1997)
5’ATCAGTATCAAAGTGAGAGTGATTGCAGTCACAATGTTTGCCACGCCCCTCAGACAGCCAGCTGCGGCTA
ACCACCAGACCCCAAAGAATTCCGCCGGCATGGATGAGCATGGTAAGCCGTATCAGTACGAGATTACCG
ATCACGGATACGGCAAGGATGCGGTCAAGGTGCTGCA
ATCACGGATACGGCAAGGATGCGGTCAAGGTGCTGCATGTCAGCCGCAACGGACCCGTGCACGCCATCC
TGTCAGCCGCAACGGACCCGTGCACGCCATCC
AGGAATTCGAGGTGGGCACTCACCTGAAGTTGTACAGCAAAAAGGATTACTACCAGGGCAACAACTCGG
ACATCGTGGCCACCGATTCGCAGAAGAACACCGTCTATTTGCTGGCGAAAAAGCATGGCATTGAAAGTCC
CGAGAAGTTTGCTCTGCTCCTGGCCAGGCACTTTATTAACAAATACTCGCACGTGGAGGAGGCGCACGTT
CATGTGGAGGCGTATCCCTGGCAGCGAGTTTGCCAGGAGGAGACCAGGACCAACGTCAATGGGAAGTGC
CCCTGGCAGCGAGTTTGCCAGGAGGAGACCAGGACCAACGTCAATGGGAAGTGC
GAGAACGGAGTCCAAGGGAACTGCGACTTCAGCTCCATTGACAACAGATCACTGCACAATCACGCTTTTA
TATTCACGCCCACCGCTCTTCACTACTGCGATGTGGTTATAAGGAGAACAGATCCCAAACAAACGGTCAT
CACGGGCATCAAGGGTCTCCGGGTGCTGAAGACGACCCAATCCTCGTTCGTGAACTTCGTGA
CACGGGCATCAAGGGTCTCCGGGTGCTGAAGACGACCCAATCCTCGTTCGTGAACTTCGTGAACGATGAG
TTCAGATCTCTGCCAGATCAGTATGATCGCATCTTTAGCACCGTGGTGGATTGCTCCTGGGAGTACTCCGA
TACCGAGAACTTGGACTTCCTCAGGGCCTGGCAAACGGTCAAAAACATAATCATTCGTAACTTTGCTGGC
GATCCGCAGGTGGGCGTGTCCTCGCCCTCCGTTCAGCACACCCTGTATCTGAGTGAAAGACAGGTCCTGG
ATGTCCTGCCGCAGGTGTCGGTCATTTCGATGACCAT
ATGTCCTGCCGCAGGTGTCGGTCATTTCGATGACCATGCCAAACAAGCACTACTTCAACTTCGATACGAA
GCCAAACAAGCACTACTTCAACTTCGATACGAA
GCCCTTCCAGAAGATTGCACCCGGCGACAACAATGAAGTTTTCATCCCAGTGGACAAGCCACATGGCACC
ATCTATGCCCAATTGGCCCGGAAGAACATCAATAGTCACCTGTAGATCGATCTCTGATGTAGTAAATCTA
AATCAATCTAAATCAATTTAGCCAATTCATAATTGCATGCGGCGAAGTTATATATGTATTTTAAATTATTT
AAGCAAACGAATCATATGCTGCGTTCTTCTTATTTAAACAATAATAAACTAATAAAAAATAAAGTGTAAA
CATATGCTGCGTTCTTCTTATTTAAACAATAATAAACTAATAAAAAATAAAGTGTAAA
AATG-3’
1997)
Tubuling 56D RA:: Common Gene 9277 (CG9277) sequence from BLAST database (Altschul et al., 1997).
5’ATAGTAGTTATACAGCTCAGTTCCAGCCCACGCCCGAAGATTCGAGTAAGATCGGTCGGCGGAACGCAAT
GACAGCTGCGCCTCGAGATCCGAAACGAAAACCCACGCCAGATGACGTTATCGTTGGTGTGGCGATGGT
GCTGCTGGTCGTGGTGGTGGAAACGCACCAAAAATGGCAGCGAATAAGT
GCTGCTGGTCGTGGTGGTGGAAACGCACCAAAAATGGCAGCGAATAAGTTATGTTAATCGGAGCTCGGC
TATGTTAATCGGAGCTCGGC
CCATACACAGAGTTTATGATGGCGTACATGGGTGGCCTAAACCACGTAGCCGAGCCCAGACATGTTTCTG
GGAGATCATCTCCGATGAGCATGGCATCGATGCCACCGGCGCCTACCACGGTGACAGCGACCTGCAGCT
GGAGCGCATCAATGTGTACTACAATGAGGCGTCCGGTGGCAAGTACGTGCCCCGCGCTGTCCTTGTCGAT
CTGGAGCCCGGCACCATGGACTCTGTG
CTGGAGCCCGGCACCATGGACTCTGTGCGATCGGGACCTTTCGGCCAGATCTTCAGGCCCGACAACTTTG
CGATCGGGACCTTTCGGCCAGATCTTCAGGCCCGACAACTTTG
TGTTCGGCCAGTCGGGTGCCGGCAACAACTGGGCCAAGGGTCATTACACAGAGGGTGCTGAGCTGGTGG
ACTCAGTGCTCGATGTTGTCCGCAAGGAGGCCGAATCCTGCGACTGCCTGCAAGGCTTCCAACTCACACA
CTCCCTTGGCGGCGGCACTGGCTCCGGTATGGGAACCCTGCTGATTTCCAAGATCCGCGAGGAGTACCCC
GACAGGATCATGAACACATACTCGGTTGTGCCGTCGCCCAAGGTGTCGGACACCGTTGTGGAGCCCTACA
GGATCATGAACACATACTCGGTTGTGCCGTCGCCCAAGGTGTCGGACACCGTTGTGGAGCCCTACA
ACGCCACCCTGTCGGTGCACCAGCTGGTCGAGAACACGGACGAGACCTACTGCATCGACAACGAGGCTC
TCTACGATATCTGCTTCCGCACCCTCAAGCTGACGACACCCACATACGGTGACCTGAACCATCTTGTCTCC
CTGACCATGTCCGGCGTAACCACCTGCCTCCGATTCCCCGGCCAACTGAA
CTGACCATGTCCGGCGTAACCACCTGCCTCCGATTCCCCGGCCAACTGAACGCTGATCTCCGCAAGCTGG
CGCTGATCTCCGCAAGCTGG
CCGTCAACATGGTGCCCTTCCCACGTCTTCACTTCTTCATGCCCGGCTTCGCTCCCCTGACCTCCCGAGGA
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TCCCAGCAGTACCGCGCCCTCACCGTGCCCGAGCTGACCCAGCAGATGTTCGATGCCAAGAACATGATGG
CCGCCTGCGACCCACGCCACGGACGCTACCTTACCGTCGCCGCCATCTTCCGTGGACGCATGTCCATGAA
GGAGGTCGACGAGCAGATGCTGAACATCCAGAACAAGAACAGCTCCTACTTCGTCGAATGGATCCCCAA
CAACGTGAAGACCGCCGTGTGCGACATCCCGCCCCGTGGTCTGAAGATGTCCGCCACCTTCATCGGCAAC
TCCACTGCCATCCAGGAGCTGTTCAAGCGCATCTCCGAGCAGTTCACCGCTATGTTCAGGCGCAAGGCTT
TCTTGCATTGGTACACCGGCGAGGGCATGGACGAGATGGAGTTCACCGAGGCCGAGAGCAACATGAACG
ATCTGGTGTCCGAGTACCAGCAGTACCAGGAGGCCACCGCCGACGAGGACGCCGAGTTCGAGGAGGAGC
AGGAGGCTGAGGTCGACGAGAACTAAATTCGAATCGGAAATCAATCGAATTCTCGATCAATGTTTTGCGA
AAAAAAATGAAACGAGAACAAATGAATTCAGTTGTAAAAGATTTGTTCTCTTAACAACGTAATCAATAA
AGTCGGATCCAATTTTGTTCACAAGTCT-3’

Figure 10: Genome of UO RNAi Line
Shown is the genome sequence of UO RNAi line on the left of arm of the 2nd chromosome.
DNA sequence of UO RNAi line:
5’AACCACCAGACCCCAAAGAATTCCGCCGGCATGGATGAGCATGGTAAGCCGTATCAGTACGAGATTACC
GATCACGGATACGGCAAGGATGCGGTCAAGGTGCTGCATGTCAGCCGCAACGGACCCGTGCACGCCATC
CAGGAATTCGAGGTGGGCACTCACCTGAAGTTGTACAGCAAAAAGGATTACTACCAGGGCAACAACTCG
GACATCGTGGCCACCGATTCGCAGAAGAACACCGTCTATTTGCTGGCGAAAAAGCATGGCATTGAAAGT
CCCGAGAAGTTTGCTCTGCTCCTGGCCAGGCACTTTATTAACAAATACTCGCACGTGGAGGAGGCGCACG
TTCATGTGGAGGCGTATNCCCTGGCAGCGAGTTTGCCAGGAGGAGACCAGGACCAACGTCAATGGGAAG
TGCGAGAACGGAGTCCAAGGGAACTGCGACTTCAGCTCCATTGACAACAGATCACTGCACAATCACGCT
TTTATATTCACGCCCAC-3’
W1118 Line
The W1118 strain is a wild type strain that serves as a genetic control and is homozygous for wild type alleles. Fly
strain was acquired from the Benz Lab at Caltech Institute of Technology, Pasadena, CA.
Da Driver Line
The Da Driver Line contains homozygous Gal4 transcription factors downstream of promoters for Da protein. The Da
protein is ubiquitously expressed throughout development and at moderate levels throughout the body of the fly (St
Pierre et al., 2014). Fly strain was acquired from the Benz Lab at Caltech Institute of Technology, Pasadena, CA.
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Figure 11: qRT-PCR of urate oxidase mRNA confirms efficient knockdown using RNAi in D. melanogaster
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(A) qRT - PCR of urate oxidase mRNA transcripts of Da > UO RNAi (urate oxidase knockdown) flies fed the stock diet until 0
d relative to Da > W1118, control flies fed the stock diet until 0 d. Tubulin 56D RA was used as loading control for ∆Ct
comparison. Shown is the ∆∆Ct of UO KD (red bar) compared to Da > W1118 (not shown). Student’s two-tailed t-test was
performed on the ∆∆Ct, *** = p < 0.001. Error bar represents 95% CI. Biological n = 11. For each biological n, 10 flies
were sacrificed.
(B) ∆Ct values from (A) of Da > UO RNAi (urate oxidase knockdown) flies fed the stock diet until 0 d relative to Da > W1118,
control flies fed the stock diet until 0 d. Tubulin 56D RA was used as loading control for ∆Ct comparison. Student’s twotailed t-test was performed on the ∆Ct, *** = p < 0.001. Error bar represents 95% CI. Biological n = 11. For each biological
n, 10 flies were sacrificed.
(C) qRT - PCR of urate oxidase mRNA transcripts of Da > UO RNAi (urate oxidase knockdown) flies fed the LP (noncheckered bars) and HP (checkered bars) diets after 7, and 14 d versus Da > W1118, control flies fed the LP and HP diets
until 7 d and 14 d. Tubulin 56D RA was used as loading control for ∆Ct comparison. Shown is the ∆∆Ct of urate oxidase
knockdown (red bars) compared to Da > W1118 (white bars) flies. Biological n = 1. For each biological n, 10 flies were
sacrificed.
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Figure 12: Uric acid levels increased with urate oxidase knockdown on the high purine diet in D. melanogaster
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Uric acid levels of DaGS > UO RNAi (urate oxidase knockdown) flies fed the LP (+) and HP (+) diets (red bars), after 7 d
and 14 d versus DaGS > UO RNAi (control) flies fed the LP (-) and HP (-) diets (white bars) after 7 d and 14 d (biological n
= 3). For each biological n, 5 flies were sacrificed. Measurements were standardized to the average weight of 5 flies. UA =
Uric Acid, RU486 (-) = null for urate oxidase knockdown, RU486 (+) = urate oxidase knockdown.
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Figure 13: Uric acid kidney stone formation in D. melanogaster was induced by urate oxidase knockdown and
dietary purine supplementation
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(A) Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the LP (+) (white bar) and HP
(+) diets (black bar) versus DaGS >UO RNAi (control) flies fed the LP (-) (grey bar) and HP (-)) (grey checkered bar) diets
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after 14 d (biological n = 3). For each biological n, 12 flies were sacrificed and dissected. One-way ANOVA was performed
on uric acid kidney stone formation, *** = p < 0.05. Error bar represents 95% CI.
(B) Uric acid kidney stone formation in Da > UO RNAi (uric oxidase knockdown) flies fed the LP (white bar) and HP (black
bar) diets versus Da > W1118 (control) flies fed the LP (grey bar) and HP (grey checkered bar) diets after 14 d (biological n
= 3). For each biological n, 12 flies were sacrificed and dissected. One-way ANOVA was performed on uric acid kidney
stone formation, ** = p < 0.01. Error bar represents 95% CI.
(C) Representative images from (Fig. 13A) taken of dissected guts from DaGS >UO RNAi (urate oxidase knockdown) flies fed
the HP (+) diet (red box) versus DaGS > UO RNAi (control) flies fed the HP (-) diet (black box). Black bar represents a
length of 500 µm.

Figure 14: Allopurinol and potassium citrate supplementation reduced uric acid kidney stone formation when urate
oxidase was knocked down and dietary purine supplemented
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(A) Uric acid kidney stone formation in Da > UO RNAi (urate oxidase knockdown) flies fed the HP diet (black bar) versus Da >
UO RNAi flies fed the HP diet supplemented with 10 µM allopurinol (red bar) after 14 d (biological n = 3). For each
biological n, 12 flies were sacrificed and dissected. *** = p < 0.001. Error bar represents 95% CI. AP = Allopurinol.
(B) Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet (black bar)
versus DaGS > UO RNAi flies fed the HP (+) diet supplemented with 10 µM allopurinol (red bar) after 14 d using micro-
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dissection (biological n = 3). For each biological n, 12 flies were sacrificed and dissected. *** = p < 0.001. Error bar
represents 95% CI. AP = Allopurinol.
(C) Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet (black bar)
versus DaGS > UO RNAi flies fed the HP (+) diet supplemented with 200 mM potassium citrate (red bar) after 14 d
(biological n = 3). For each biological n, 12 flies were sacrificed and dissected. *** = p < 0.001. Error bar represents 95%
CI. KCit = Potassium Citrate.
(D) Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet (black bar) and
HP (+) diet supplemented with 10 mM potassium citrate (red bar), 50 mM potassium citrate, 100 mM potassium citrate, and
200 mM potassium citrate after 14 d (biological n = 1). For each biological n, 12 flies were sacrificed and dissected.

Figure 15: Methotrexate, hydrochlorothiazide, and l-lysine supplementation reduced uric acid kidney stone formation
when urate oxidase was knocked down and dietary purine supplemented
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(A) Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diets supplemented
with 10 µM (non-black solid bars), 100 µM (stripped bars), and 1000 µM (checkered bars) l-lysine (blue bars),
hydrochlorothiazide (white bars), and methotrexate (red bars) versus DaGS > UO RNAi (control) flies fed the HP (-) diet
(black bar) after 14 d (biological n = 3). For each biological n, 12 flies were sacrificed and dissected. *** = p < 0.001. Error
bar represents 95% CI. L-Lys = l-lysine, HCT = hydrochlorothiazide, and MTX = methotrexate.
(B) Uric acid kidney stone formation in Da > UO RNAi (urate oxidase knockdown) flies fed the LP diet (white bar), HP diet
(black bar), HP diet supplemented with 5 µM (red solid bar), 50 µM methotrexate (red stripped bar), and 500 µM
methotrexate versus Da >W, control flies fed the LP (grey bar) and HP (grey checkered bar) diet after 14 d (biological n =
3). For each biological n, 12 flies were sacrificed and dissected. *** = p < 0.001. Error bar represents 95% CI. MTX =
methotrexate.
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Figure 16: Possible mechanisms by which allopurinol, potassium citrate, l-lysine, and methotrexate reduced uric acid
kidney stone formation

A simplified overview of purine metabolism with homologous components between D. melanogaster and humans and the
possible mechanisms by which, AP=Allopurinol, KCit=Potassium Citrate, L-Lys = L-Lysine, and MTX = Methotrexate
reduces uric acid and uric acid kidney stones. Allopurinol inhibits xanthine oxidase, the enzyme that converts xanthine into
uric acid. Potassium citrate alkalizes and increases the pH of urine, which drives the formation of more soluble urate. Llysine is also an alkalizer and increases the pH of urine, which drives the formation of more soluble urate. Methotrexate, an
inhibitor of dihydrofolate reductase, prevents the essential conversion of dihydrofolate into tetrahydrofolate for purine
synthesis, thus reducing the purine load and subsequently reducing uric acid and uric acid kidney stone formation.
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Figure 17: Possible mechanisms by which hydrochlorothiazide reduced uric acid kidney stone formation

A diagram of basolateral cells of the human nephron and D. melanogaster malpighian tubules and the possible mechanism
by which inhibition of Na+Cl- co-transporter by hydrochlorothiazide increases urine output and reduces uric acid kidney
stone formation. Na+Cl- co-transporters facilitate the movement of Na+ and Cl-, creating an osmotic gradient that causes the
passive movement of water from the lumen to basolateral side. Inhibition of Na+Cl- co-transporters prevents the movement
of Na+ and subsequently water from the lumen to the basolateral side, which increases in urine volume. The increased urine
volume causes the expulsion of small and medium sized stones. HCT = Hydrochlorothiazide.
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Figure 18: Seven Inhibitors and six enhancers of uric acid kidney stone formation were found in a medium throughput
screen of 117 compounds
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Inhibitors ( < 20% stone formers) and enhancer ( > 20 % stone formers) from medium throughput screen of 117 compounds.
Uric acid kidney stone formation in DaGS > UO RNAi (urate oxidase knockdown) flies fed the HP (+) diet supplemented
with synthetic purines (adenine = 10 mM and guanine = 10mM) and topped with 1:50 dimethyl sulfoxide solution
(reference control, n = 3, grey bar), the HP (+) diet supplemented synthetic purines and topped with 200 µM of MTX (n = 3,
red bar) in 1:50 dimethyl sulfoxide solution (positive control, red bar), and the HP (+) diet supplemented synthetic purines
and topped with compounds dissolved in 1:50 dimethyl sulfoxide from the 117 compound library (n=1). For each biological
n, 6-15 flies were sacrificed and dissected. MTX = methotrexate. DMSO = dimethyl sulfoxide.
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12 Appendix
12.1 Original Data
Figure 19: Original Data
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